[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1098
1. Hori T, Taniguchi K, Kurata M, Nakamura K, Kato K, Ogura Y, Iwasaki M, Okamoto S, Yamakado K, Yagi S, Iida T, Kato T, Saito K, Wang L, Kawarada Y, Uemoto S: Carcinoembryonic antigen-producing adrenal adenoma resected using combined lateral and anterior transperitoneal laparoscopic surgery. World J Gastroenterol; 2007 Dec 7;13(45):6094-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fluorodeoxyglucose positron emission tomography showed increased uptake in the adrenal tumor only, with a maximum standardized uptake value of 2.8.
  • Selective venography and blood sampling revealed that the concentrations of cortisol, catecholamines and CEA were significantly elevated in the vein draining the tumor.
  • A diagnosis of CEA-producing benign adenoma was made.
  • Histopathological examination revealed a benign adenoma.
  • [MeSH-minor] Aged. Female. Humans. Peritoneum / surgery

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18023107.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  • [Number-of-references] 11
  • [Other-IDs] NLM/ PMC4250898
  •  go-up   go-down


2. Ilić I, Randelović P, Ilić R, Dordević L, Radojković D: [Granular-cell tumor: a rare variant of mammary tumor]. Vojnosanit Pregl; 2008 Jun;65(6):488-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Granular-cell tumor: a rare variant of mammary tumor].
  • BACKGROUND: Granular cell tumor (GCT) is a rare variant of mammary tumor beset with diagnostic dilemmas that may be resolved by using numerous, very complex, enzymohistochemical and immunohistochemical methods.
  • CASE REPORTS: We reported three female patients 16, 21 and 65 years old, operated on for mammary tumor at the Surgical Clinic of the School of Medicine in Nis, over the period of thirty years, 1977 to 2007.
  • These tumors had benign characteristics, without associated tumors in other localizations.
  • The ultrastructural analysis confirmed that the tumor cells were enriched by lysosomes and consequential disorganization of cytoplasm.
  • CONCLUSION: The reported enzymo- and immunohistochemical combined methods provide a precise diagnosis and confirm the GCT's neural origin, which has been disputed for years.
  • [MeSH-major] Breast Neoplasms / pathology. Granular Cell Tumor / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18672708.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


3. Liu Y, Wang G, Xu WG, Song JN, Yang XQ, Wang WY: [Relevance of tumor angiogenesis in occurrence and development of breast cancer]. Zhonghua Yi Xue Za Zhi; 2009 Jun 23;89(24):1687-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relevance of tumor angiogenesis in occurrence and development of breast cancer].
  • OBJECTIVE: To detect the differential expression of vascular endothelial growth factor (VEGF) and microvessel density (MVD) count in benign and malignant breast lesions to clarify the correlation of VEGF expression with the occurrence and progression of breast cancer and angiogenesis.
  • METHODS: Immunohistochemistry (SP method) was used to examine the expression of VEGF and MVD count in 88 intra-operatively harvested samples of invasive ductal breast carcinoma, 25 samples of breast carcinoma in situ, 15 samples of atypical breast hyperplasia and 100 samples of benign breast lesions obtained.
  • RESULTS: The positive rate of VEGF in invasive ductal breast carcinoma group was 70.5% and it was significantly higher than those of benign breast lesions, atypical breast hyperplasia and breast carcinoma in situ groups ( 22.0%, 33.3% and 56.0% respectively, P = 0.000).
  • The MVD value of invasive ductal breast carcinoma group was 23 +/- 15 and it was significantly higher than those of benign breast lesions, atypical breast hyperplasia and breast carcinoma in situ groups (14 +/- 4, 18 +/- 4 and 20 +/- 6 respectively, P = 0.000).
  • In invasive ductal breast carcinoma group, a significant higher MVD value was observed as the tissue differentiation degree increased (P = 0.006).
  • In invasive ductal breast carcinoma, the MVD count increased significantly with the elevated expression of VEGF (P = 0.000).
  • CONCLUSION: In invasive ductal breast carcinoma, angiogenesis and metastasis are mediated mainly by VEGF.
  • The expressions of VEGF and MVD may be two of reference predictors for biological behaviors of breast carcinoma The occurrence and progression of breast cancer might be correlated with the expression of VEGF.
  • [MeSH-major] Breast Neoplasms / blood supply. Breast Neoplasms / pathology. Neovascularization, Pathologic
  • [MeSH-minor] Female. Humans. Microcirculation. Neoplasm Staging. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19957527.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


Advertisement
4. Yavelsky V, Rohkin S, Shaco-Levy R, Tzikinovsky A, Amir T, Kohn H, Delgado B, Rabinovich A, Piura B, Chan G, Kalantarov G, Trakht I, Lobel L: Native human autoantibodies targeting GIPC1 identify differential expression in malignant tumors of the breast and ovary. BMC Cancer; 2008;8:247
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Native human autoantibodies targeting GIPC1 identify differential expression in malignant tumors of the breast and ovary.
  • We previously described the isolation and characterization of two fully human monoclonal antibodies, 27.F7 and 27.B1, from breast cancer patients that target the protein known as GIPC1, an accessory PDZ-domain binding protein involved in regulation of G-protein signaling.
  • Human monoclonal antibodies, 27.F7 and 27.B1, to GIPC1 demonstrate specific binding to malignant breast cancer tissue with no reactivity with normal breast tissue.
  • To further clarify the association of GIPC1 with breast and ovarian cancer we carefully studied 27.F7 and 27.B1 using immunocytochemical and immunohistochemical techniques.
  • An immunohistochemical study of normal ovarian tissue, benign, borderline and malignant ovarian serous tumors, and different types of breast cancer revealed high expression of GIPC1 protein in neoplastic cells.
  • Examination of different types of breast cancer demonstrates that the level of GIPC1 expression depends on tumor invasiveness and displays a higher expression than in benign tumors.
  • CONCLUSION: The present pilot study demonstrates that the GIPC1 protein is overexpressed in ovarian and breast cancer, which may provide an important diagnostic and prognostic marker and will constitute the basis for further study of the role that this protein plays in malignant diseases.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / biosynthesis. Adaptor Proteins, Signal Transducing / immunology. Autoantibodies / chemistry. Breast Neoplasms / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Antibodies, Monoclonal / chemistry. Breast / metabolism. Cell Line, Tumor. Disease Progression. Enzyme-Linked Immunosorbent Assay / methods. Female. Humans. Immunohistochemistry / methods. Pilot Projects

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Ther. 2001 Jan;23(1):146-59 [11219474.001]
  • [Cites] Biosens Bioelectron. 2007 Feb 15;22(7):1508-16 [16904309.001]
  • [Cites] Curr Opin Oncol. 2001 Sep;13(5):399-402 [11555720.001]
  • [Cites] J Biol Chem. 2001 Oct 26;276(43):39608-17 [11546783.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jan 25;290(3):1030-6 [11798178.001]
  • [Cites] Breast Cancer Res Treat. 2002 Jan;71(2):103-12 [11881908.001]
  • [Cites] J Am Soc Nephrol. 2002 Apr;13(4):918-27 [11912251.001]
  • [Cites] Int J Mol Med. 2002 May;9(5):509-13 [11956658.001]
  • [Cites] Int J Mol Med. 2002 Jun;9(6):585-9 [12011974.001]
  • [Cites] Hum Antibodies. 2002;11(3):85-96 [12454369.001]
  • [Cites] Hybrid Hybridomics. 2002 Dec;21(6):405-14 [12573104.001]
  • [Cites] Cancer Immunol Immunother. 2004 Mar;53(3):204-16 [14722672.001]
  • [Cites] Eur J Gynaecol Oncol. 2004;25(2):207-10 [15032283.001]
  • [Cites] Curr Opin Obstet Gynecol. 2004 Feb;16(1):5-9 [15128001.001]
  • [Cites] Ann Oncol. 2004;15 Suppl 1:I18-I26 [15280183.001]
  • [Cites] CMAJ. 2004 Aug 17;171(4):323-4 [15313987.001]
  • [Cites] J Cell Biol. 1995 Jul;130(1):67-77 [7790378.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15203-8 [8986788.001]
  • [Cites] Mol Biol Cell. 1999 Apr;10(4):819-32 [10198040.001]
  • [Cites] Arch Biochem Biophys. 2006 Oct 15;454(2):160-9 [16962991.001]
  • [Cites] Curr Opin Obstet Gynecol. 2001 Feb;13(1):61-4 [11176234.001]
  • (PMID = 18721484.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antibodies, Monoclonal; 0 / Autoantibodies; 0 / GIPC1 protein, human
  • [Other-IDs] NLM/ PMC2535783
  •  go-up   go-down


5. Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M, Alavi A: Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat; 2006 Aug;98(3):267-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer.
  • METHODS: A total of 116 breast lesions in 111 patients (pre-menopausal 45; perimenopausal 15; post-menopausal 51) with known or suspicious of breast cancer who underwent FDG-PET scans for staging, were included in this study.
  • RESULTS: Of 116 breast lesions, 85 were malignant and 31 were benign on histopathology.
  • Among the 31 benign lesions, 30 were true negative and one was false positive.
  • There was significant difference in the tumor size (p=0.003) and tumor grade (p=0.001) in patients with TP and FN PET results.
  • Multivariate logistic regression demonstrated that tumor size (< or =10 mm) and low tumor grade were independently associated with FN results.
  • No significant relationship of FN PET results was found with age, menopausal status, tumor type, c-erbB-2, estrogen and progesterone receptors, sentinel lymph node or distant metastasis, parenchymal density and multifocality of primary breast tumor.
  • CONCLUSION: In present study, tumor size and tumor grade are independent factors that predict FDG-PET results.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. False Negative Reactions. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Image Processing, Computer-Assisted. Lymph Nodes / pathology. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Neoplasm Staging. Regression Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16555126.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01-RR00040
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


6. Ding Y, Ruan Q: The value of p63 and CK5/6 expression in the differential diagnosis of ductal lesions of breast. J Huazhong Univ Sci Technolog Med Sci; 2006;26(4):405-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of p63 and CK5/6 expression in the differential diagnosis of ductal lesions of breast.
  • In order to explore the value of p63, smoothmuscle actin (alpha-SMA) and cytokeratin 5/6 (CK5/6) in the differential diagnosis of ductal lesions of breast, 88 tissue specimens of ductal lesions of breast were collected and examined histologically by HE staining.
  • The results showed that in 38 cases of benign breast lesions, the proliferating cells were all positive for p63 and alpha-SMA.
  • In 38 cases of benign breast lesions, the positive rate of CK5/6 expression was 100%.
  • In 19 cases of CDIS, no tumor cells expressed CK5/6.
  • It was suggested that p63 could serve as a novel specific marker for the identification of breast myoepithelial cells.
  • Simultaneous detection of p63, CK5/6 and alpha-SMA can help increase the diagnostic accuracy of breast diseases.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Keratin-5 / biosynthesis. Keratin-6 / biosynthesis. Membrane Proteins / biosynthesis
  • [MeSH-minor] Breast Diseases / diagnosis. Breast Diseases / metabolism. Diagnosis, Differential. Female. Fibrocystic Breast Disease / diagnosis. Humans. Immunohistochemistry. Papilloma, Intraductal / diagnosis. Papilloma, Intraductal / metabolism. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2002 Apr;15(4):397-405 [11950913.001]
  • [Cites] Virchows Arch. 2003 Jun;442(6):548-54 [12712335.001]
  • [Cites] Histopathology. 2005 Aug;47(2):202-8 [16045782.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):82-90 [12502930.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1054-60 [11474290.001]
  • [Cites] Adv Anat Pathol. 2002 Sep;9(5):280-9 [12195217.001]
  • [Cites] In Vivo. 2003 Nov-Dec;17(6):573-6 [14758723.001]
  • (PMID = 17120733.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Keratin-5; 0 / Keratin-6; 0 / Membrane Proteins
  •  go-up   go-down


7. Yang WT, Hennessy B, Broglio K, Mills C, Sneige N, Davis WG, Valero V, Hunt KK, Gilcrease MZ: Imaging differences in metaplastic and invasive ductal carcinomas of the breast. AJR Am J Roentgenol; 2007 Dec;189(6):1288-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging differences in metaplastic and invasive ductal carcinomas of the breast.
  • OBJECTIVE: The purpose of this study was to compare the imaging features of metaplastic breast carcinoma with those of invasive ductal carcinoma.
  • MATERIALS AND METHODS: Women diagnosed on preoperative mammography or sonography with metaplastic breast carcinoma and T-stage matched invasive ductal carcinoma of the breast from a single pathology database were included in the study.
  • RESULTS: Forty-three patients diagnosed with metaplastic carcinoma were matched to 43 patients with ductal carcinoma by tumor T stage.
  • These carcinomas tend to show more benign imaging features, such as round or oval shape with circumscribed margins, when compared with ductal carcinomas.
  • [MeSH-major] Breast Neoplasms / radiography. Breast Neoplasms / ultrasonography. Carcinoma, Ductal, Breast / radiography. Carcinoma, Ductal, Breast / ultrasonography. Mammography / methods
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Metaplasia / radiography. Metaplasia / ultrasonography. Middle Aged. Reproducibility of Results. Sensitivity and Specificity. Ultrasonography, Mammary / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18029860.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Wen W, Ren Z, Shu XO, Cai Q, Ye C, Gao YT, Zheng W: Expression of cytochrome P450 1B1 and catechol-O-methyltransferase in breast tissue and their associations with breast cancer risk. Cancer Epidemiol Biomarkers Prev; 2007 May;16(5):917-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cytochrome P450 1B1 and catechol-O-methyltransferase in breast tissue and their associations with breast cancer risk.
  • Cytochrome P450 1B1 (CYP1B1) and catechol-O-methyltransferase (COMT) are important estrogen-metabolizing enzymes that may affect breast cancer risk.
  • Few studies have directly measured the expression of CYP1B1 and COMT genes in breast tissue samples.
  • The subjects in this study were a subgroup of participants of the Shanghai Breast Cancer Study including 64 patients diagnosed with breast cancer and 68 patients diagnosed with benign breast diseases (BBD) who provided samples of tumor tissue and adjacent nontumor tissue to the study.
  • We compared CYP1B1 and COMT mRNA expression in tumor tissue and adjacent nontumor tissue in both breast cancer patients and BBD patients.
  • High levels of CYP1B1 expression and low levels of COMT expression in adjacent nontumor tissue were associated with a significantly increased breast cancer risk in a nonlinear manner.
  • These results support the hypothesis that the formation and accumulation of catechol estrogens in breast tissue through increased CYP1B1 expression and reduced COMT expression may play a significant role in breast cancer risk.
  • [MeSH-major] Aryl Hydrocarbon Hydroxylases / genetics. Breast / enzymology. Breast Neoplasms / genetics. Catechol O-Methyltransferase / genetics. Gene Expression Regulation, Enzymologic / physiology
  • [MeSH-minor] Adult. Breast Diseases / enzymology. Breast Diseases / epidemiology. Breast Diseases / genetics. Case-Control Studies. China / epidemiology. Confidence Intervals. Cytochrome P-450 CYP1B1. Estrogens / metabolism. Female. Genotype. Humans. Logistic Models. Middle Aged. Odds Ratio. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17507616.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA64277; United States / NCI NIH HHS / CA / R01CA90899
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / CYP1B1 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP1B1; EC 2.1.1.6 / Catechol O-Methyltransferase
  •  go-up   go-down


9. Zhang W, Yang YC, Zhang BN, Pan QJ, Hart SD, Duvall K, Zhang ZF, Rao JY: Biomarker analysis on breast ductal lavage cells in women with and without breast cancer. Int J Cancer; 2006 Jul 15;119(2):359-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomarker analysis on breast ductal lavage cells in women with and without breast cancer.
  • Recent studies show that morphology based analysis of ductal lavage specimens failed to detect many cancers in women with breast cancer.
  • Such an observation raises doubts about the potential role of ductal lavage in an individual's risk assessment and early detection of breast cancer.
  • We hypothesize that biomarker-based analysis using markers of malignancy field defects including DNA 5c exceeding rate (DNA 5cER) and G-actin might provide a more reliable test for breast cancer risk.
  • For the training phase, 36 Chinese women were recruited (13 with breast cancer, 8 with intraductal papilloma and 15 with benign breast diseases).
  • Quantitative analysis of biomarkers for G-actin and DNA5cER is feasible and useful in distinguishing benign from malignant breast disease on archived ductal lavage slides.
  • [MeSH-major] Actins / analysis. Biomarkers, Tumor / analysis. Breast Diseases / metabolism. Breast Neoplasms / chemistry. Carcinoma, Intraductal, Noninfiltrating / chemistry. Estrogens, Conjugated (USP) / analysis. Mammary Glands, Human / chemistry
  • [MeSH-minor] Adult. Aged. Biomarkers / analysis. China. Cytodiagnosis. DNA, Neoplasm / analysis. Feasibility Studies. Female. Humans. Laser Scanning Cytometry. Middle Aged. Predictive Value of Tests. Reproducibility of Results. Risk Assessment. Sensitivity and Specificity. Therapeutic Irrigation

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • (PMID = 16477639.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Estrogens, Conjugated (USP)
  •  go-up   go-down


10. Ma X, Chen C, Xiong H, Li Y: Transforming growth factorβ1 L10P variant plays an active role on the breast cancer susceptibility in Caucasian: evidence from 10,392 cases and 11,697 controls. Breast Cancer Res Treat; 2010 Nov;124(2):453-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transforming growth factorβ1 L10P variant plays an active role on the breast cancer susceptibility in Caucasian: evidence from 10,392 cases and 11,697 controls.
  • In view of the essential role of transforming growth factorβ1 (TGFB1) on both inhibiting the development of early benign breast tumors as well as promoting tumor invasion, the association of TGFB1 L10P polymorphism and breast cancer risk has been widely reported, but results of previous studies were somewhat contradictory and underpowered.
  • To overcome the limitations of individual study and to understand the real situation, we conducted a systematic review and meta-analysis towards the association between TGFB1 L10P polymorphism and breast cancer.
  • Conclusively, this meta-analysis strongly suggests that TGFB1 L10P polymorphism may play a low penetrance role in breast cancer susceptibility in Caucasian.
  • [MeSH-major] Breast Neoplasms / genetics. European Continental Ancestry Group / genetics. Polymorphism, Genetic. Transforming Growth Factor beta1 / genetics
  • [MeSH-minor] Case-Control Studies. Female. Gene Frequency. Genetic Predisposition to Disease. Humans. Neoplasm Invasiveness. Odds Ratio. Phenotype. Risk Assessment. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20349130.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / TGFB1 protein, human; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


11. Isla Larrain M, Demichelis S, Crespo M, Lacunza E, Barbera A, Cretón A, Terrier F, Segal-Eiras A, Croce MV: Breast cancer humoral immune response: involvement of Lewis y through the detection of circulating immune complexes and association with Mucin 1 (MUC1). J Exp Clin Cancer Res; 2009;28:121
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer humoral immune response: involvement of Lewis y through the detection of circulating immune complexes and association with Mucin 1 (MUC1).
  • METHODS: Pretreatment serum and tissue breast samples from 76 adenocarcinoma, 34 benign and 36 normal specimens were analyzed.
  • Immunoprecipitation (IP) was performed in 9 malignant, benign and normal samples and analyzed by SDS-PAGE and Western blot.
  • RESULTS: By ELISA, Lewis y/IgM/CIC levels showed statistically significant differences between breast cancer versus benign and normal samples; mean +/- SD values expressed in OD units were: 0.525 +/- 0.304; 0.968 +/- 0.482 and 0.928 +/- 0.447, for breast cancer, benign disease and normal samples, respectively, p < 0.05.
  • By IHC, with C14 MAb, 47.5%, 31% and 35% of malignant, benign and normal samples, respectively, showed positive reaction while all the samples were positive with anti-MUC1 MAb; in both cases, with a different pattern of expression between malignant and non malignant samples.
  • CONCLUSION: Our findings support that in breast cancer there was a limited humoral immune response through Lewis y/IgM/CIC levels detection which correlated with MUC1/IgM/CIC.
  • [MeSH-major] Antigen-Antibody Complex / blood. Breast Neoplasms / blood. Breast Neoplasms / immunology. Immunity, Humoral. Lewis Blood-Group System / blood. Mucin-1 / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Biomarkers, Tumor / immunology. Blotting, Western. Electrophoresis, Polyacrylamide Gel. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Immunoprecipitation. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 May 1;164(9):4868-77 [10779796.001]
  • [Cites] Mol Immunol. 2009 Nov;47(1):52-6 [19217667.001]
  • [Cites] J Leukoc Biol. 2000 Oct;68(4):511-4 [11037972.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3264-9 [11248067.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Jul;6(3):355-64 [11547903.001]
  • [Cites] Rheumatology (Oxford). 2001 Sep;40(9):1033-7 [11561115.001]
  • [Cites] Glycoconj J. 2001 Nov-Dec;18(11-12):895-906 [12820723.001]
  • [Cites] Expert Rev Vaccines. 2002 Aug;1(2):193-206 [12901558.001]
  • [Cites] Breast Cancer Res Treat. 2003 Oct;81(3):195-207 [14620915.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):1087-93 [14871842.001]
  • [Cites] Biochim Biophys Acta. 2004 Jun 11;1672(3):157-63 [15182935.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] Lancet. 1982 Nov 6;2(8306):999-1005 [6127540.001]
  • [Cites] J Immunol. 1983 Jul;131(1):508-13 [6190927.001]
  • [Cites] Int J Cancer. 1984 Jun 15;33(6):727-36 [6203846.001]
  • [Cites] Allergol Immunopathol (Madr). 1984 May-Jun;12(3):225-32 [6382986.001]
  • [Cites] Nature. 1985 Mar 7-13;314(6006):53-7 [2579340.001]
  • [Cites] J Immunol. 1985 Sep;135(3):1911-3 [2410505.001]
  • [Cites] Contemp Top Immunobiol. 1985;15:55-109 [3896644.001]
  • [Cites] Cancer Res. 1987 May 15;47(10):2531-6 [2436750.001]
  • [Cites] Cancer Res. 1987 Nov 1;47(21):5566-71 [2444333.001]
  • [Cites] Gan To Kagaku Ryoho. 1989 Mar;16(3 Pt 2):715-31 [2468313.001]
  • [Cites] Cancer Res. 1990 Apr 1;50(7):2183-90 [1690595.001]
  • [Cites] Cancer Res. 1991 Jan 15;51(2):718-23 [1985789.001]
  • [Cites] Biochemistry. 1991 Apr 2;30(13):3328-34 [2009271.001]
  • [Cites] Targeted Diagn Ther. 1989;2:1-39 [2519542.001]
  • [Cites] Int J Cancer. 1992 Jan 2;50(1):57-63 [1728614.001]
  • [Cites] Glycobiology. 1999 Dec;9(12):1337-45 [10561459.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):574-83 [10653872.001]
  • [Cites] Br J Cancer. 1995 Oct;72(4):934-8 [7547243.001]
  • [Cites] Eur J Biochem. 1996 Feb 15;236(1):318-27 [8617281.001]
  • [Cites] Int J Cancer. 1996 May 29;66(5):617-23 [8647622.001]
  • [Cites] Mol Biol Cell. 1996 Apr;7(4):565-77 [8730100.001]
  • [Cites] Eur J Cancer. 1996 Jul;32A(8):1325-31 [8869094.001]
  • [Cites] Glycobiology. 1996 Sep;6(6):635-46 [8922959.001]
  • [Cites] Semin Cancer Biol. 1995 Dec;6(6):357-66 [8938274.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6D):4287-92 [9494522.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R780-7 [16168124.001]
  • [Cites] Hum Vaccin. 2006 May-Jun;2(3):137-43 [17012906.001]
  • [Cites] Pathol Oncol Res. 2007;13(2):130-8 [17607374.001]
  • [Cites] N Engl J Med. 2008 Jun 19;358(25):2704-15 [18565863.001]
  • [Cites] J Exp Clin Cancer Res. 2009;28:118 [19695088.001]
  • [Cites] Int J Cancer. 2000 Jun 1;86(5):702-12 [10797294.001]
  • (PMID = 19715603.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigen-Antibody Complex; 0 / Biomarkers, Tumor; 0 / Lewis Blood-Group System; 0 / Lewis Y antigen; 0 / Mucin-1
  • [Other-IDs] NLM/ PMC2743658
  •  go-up   go-down


12. Moon HJ, Kim MJ, Kwak JY, Yoon JH, Kim SJ, Sohn YM, Kim EK: Malignant lesions initially categorized as probably benign breast lesions: retrospective review of ultrasonographic, clinical and pathologic characteristics. Ultrasound Med Biol; 2010 Apr;36(4):551-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lesions initially categorized as probably benign breast lesions: retrospective review of ultrasonographic, clinical and pathologic characteristics.
  • The primary objective of this study was to review the ultrasonographic features of BI-RADS category 3 ("probably benign") lesions that eventually proved to be malignant.
  • Thirty-two (0.8%) of 4000 women with lesions that were initially classified as "probably benign" proved to be malignant and formed the study group.
  • There was no statistical difference in the mean age, mean size of lesions, or tumor stage between patients who underwent early biopsy (n = 19) or biopsy after 6 months (n = 13).
  • [MeSH-major] Biopsy / statistics & numerical data. Breast Neoplasms / diagnosis. Breast Neoplasms / epidemiology. Ultrasonography, Mammary / statistics & numerical data
  • [MeSH-minor] Adult. Aged. Female. Humans. Korea / epidemiology. Male. Middle Aged. Prevalence. Reproducibility of Results. Retrospective Studies. Risk Assessment. Risk Factors. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20350681.001).
  • [ISSN] 1879-291X
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


13. Schiffmann S, Sandner J, Birod K, Wobst I, Angioni C, Ruckhäberle E, Kaufmann M, Ackermann H, Lötsch J, Schmidt H, Geisslinger G, Grösch S: Ceramide synthases and ceramide levels are increased in breast cancer tissue. Carcinogenesis; 2009 May;30(5):745-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ceramide synthases and ceramide levels are increased in breast cancer tissue.
  • Several in vitro studies have correlated dysfunction of the sphingolipid-signaling pathway with promotion of tumor cell growth as well as progression and resistance of tumors to chemotherapeutic agents.
  • As ceramides (Cer) constitute the structural backbones of all sphingolipids, we investigated the endogenous ceramide levels in 43 malignant breast tumors and 21 benign breast biopsies and compared them with those of normal tissues using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS).
  • The total ceramide levels in malignant tumor tissue samples were statistically significantly elevated when compared with normal tissue samples.
  • Upregulation of the total ceramide level averaged 12-fold and 4-fold higher than normal tissue samples, for malignant tumors and benign tissues, respectively.
  • Specifically, the levels of C(16:0)-Cer, C(24:1)-Cer and C(24:0)-Cer were significantly raised in malignant tumors as compared with benign and normal tissue.
  • Moreover, the levels of C(18:0)-Cer and C(20:0)-Cer were significantly higher in estrogen receptor (ER) positive tumor tissues as compared with ER negative tumor tissues.
  • In conclusion, progression in breast cancer is associated with increased ceramide levels due to an upregulation of specific LASS genes.
  • [MeSH-major] Breast Neoplasms / enzymology. Breast Neoplasms / metabolism. Ceramides / metabolism. Oxidoreductases / metabolism
  • [MeSH-minor] Breast / enzymology. Breast / metabolism. Breast Diseases / metabolism. Breast Diseases / pathology. Cell Division. Female. Humans. Membrane Proteins / genetics. RNA, Messenger / genetics. Receptors, Estrogen / metabolism. Reference Values. Sphingolipids / metabolism. Sphingosine N-Acyltransferase. Up-Regulation

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19279183.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ceramides; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / Receptors, Estrogen; 0 / Sphingolipids; EC 1.- / Oxidoreductases; EC 1.3.1.- / dihydroceramide desaturase; EC 2.3.1.24 / CERS6 protein, human; EC 2.3.1.24 / Sphingosine N-Acyltransferase
  •  go-up   go-down


14. Solanas M, Grau L, Moral R, Vela E, Escrich R, Escrich E: Dietary olive oil and corn oil differentially affect experimental breast cancer through distinct modulation of the p21Ras signaling and the proliferation-apoptosis balance. Carcinogenesis; 2010 May;31(5):871-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary olive oil and corn oil differentially affect experimental breast cancer through distinct modulation of the p21Ras signaling and the proliferation-apoptosis balance.
  • Extra-virgin olive oil (EVOO) has been hypothesized to have chemopreventive effects on breast cancer, unlike high corn oil (HCO) diets that stimulate it.
  • We analyzed the tumor mitotic index, proliferating cell nuclear antigen (PCNA) levels, and apoptosis through Caspase-3 analysis and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling assays.
  • Tumors from rats fed the EVOO diet displayed a more benign phenotype, whereas those from rats fed the HCO diet were biologically more aggressive.
  • In conclusion, high EVOO and corn oil diets exert their modulatory effects on breast cancer through a different combination of Ras signaling pathways, a different proliferation-apoptosis balance and probably distinct levels of DNA damage.
  • [MeSH-minor] Animals. Cell Proliferation / drug effects. Deoxyguanosine / analogs & derivatives. Deoxyguanosine / analysis. Extracellular Signal-Regulated MAP Kinases / physiology. Female. Mutation. Olive Oil. Proto-Oncogene Proteins c-akt / metabolism. Rats. Rats, Sprague-Dawley. Receptor, ErbB-2 / analysis


15. Sharma U, Danishad KK, Seenu V, Jagannathan NR: Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed; 2009 Jan;22(1):104-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
  • Measurements of tumor apparent diffusion coefficient (ADC), volume and diameter in assessing the response of patients with locally advanced breast cancer (LABC) (n = 56) undergoing neoadjuvant chemotherapy (NACT) at four time periods (before treatment and after three cycles of NACT) were carried out at 1.5 T using diffusion-weighted imaging (DWI) and MRI.
  • Ten benign tumors and 15 controls were also investigated.
  • The MR tumor response was compared with the clinical response.
  • Mean ADC before treatment of malignant breast tissue was significantly lower than that of controls, disease-free contralateral tissue of the patients, and benign lesions, and gradually increased during the course of NACT.
  • A cut-off value of ADC was also calculated using receiver operator characteristics analysis to discriminate between normal, benign and malignant breast tissue.
  • Similarly, a cut-off value for ADC, volume and diameter was obtained after the second and third cycles of NACT to predict tumor response.
  • The results show that ADC is more useful for predicting early tumor response to NACT than morphological variables, suggesting its potential in effective treatment management.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Diffusion Magnetic Resonance Imaging. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Diffusion. Female. Humans. Longitudinal Studies. Middle Aged. Sensitivity and Specificity. Time Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18384182.001).
  • [ISSN] 0952-3480
  • [Journal-full-title] NMR in biomedicine
  • [ISO-abbreviation] NMR Biomed
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


16. Oddsson SJ, Kristvinsson H, Jónsson JG, Torfason B, Gudbjartsson T: [Desmoid tumor of chest wall--an important differential diagnosis to malignancies]. Laeknabladid; 2006 Nov;92(11):777-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Desmoid tumor of chest wall--an important differential diagnosis to malignancies].
  • They are classified as benign as they do not metastasize.
  • Their histological appearance can also resemble some malignant neoplasms such as low grade sarcomas, rendering the differential diagnosis difficult.
  • At follow-up 4 years later, a solid nodule was palpated below the right breast.
  • The tumor increased in size over several weeks and caused local radiating chest pain.
  • Clinically a breast cancer metastasis was suspected.
  • Open biopsy revealed a desmoid tumor.
  • The tumor was resected together with a part of the anterior hemithorax, and the defect in the chest wall covered with a Goretex-patch.
  • [MeSH-major] Fibromatosis, Aggressive / diagnosis. Thoracic Neoplasms / diagnosis. Thoracic Wall / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Desmoid Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17093329.001).
  • [ISSN] 0023-7213
  • [Journal-full-title] Læknablađiđ
  • [ISO-abbreviation] Laeknabladid
  • [Language] ice
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Iceland
  •  go-up   go-down


17. Glazebrook KN, Reynolds CA: Mammary fibromatosis. AJR Am J Roentgenol; 2009 Sep;193(3):856-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: Mammary fibromatosis is a rare, benign, nonmetastasizing stromal tumor.
  • It presents clinically and radiologically as a palpable, spiculated, and locally invasive tumor that is suspicious for malignancy.
  • Although histologically benign, the tumor is locally aggressive and has significant recurrence rates.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms, Male / diagnosis. Fibroma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Ultrasonography, Mammary

  • Genetic Alliance. consumer health - Fibromatosis.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19696302.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Juretzka MM, Crawford CL, Lee C, Wilton A, Schuman S, Chi DS, Sonoda Y, Barakat RR, Abu-Rustum NR: Laparoscopic findings during adnexal surgery in women with a history of nongynecologic malignancy. Gynecol Oncol; 2006 May;101(2):327-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prior cancer history included breast (202, 77.1%), lymphoma/leukemia (16, 6.1%), colorectal (8, 3.0%), lung (7, 2.7%), multiple myeloma (5, 1.9%), head/neck (5, 1.9%), genitourinary (5, 1.9%), upper gastrointestinal (4, 1.5%), and other (10, 3.8%).
  • Median tumor diameter and CA-125 were significantly higher in women found to have a malignancy (4.7 vs. 3.7 cm, and 35 vs. 14 U/mL, respectively).
  • Twenty-one of 49 (42.9%) patients with malignancy were converted to laparotomy compared with 13/213 (6.1%) when benign disease was noted (P < 0.001).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Laparoscopy. Middle Aged. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16360202.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Ben Hassouna J, Damak T, Gamoudi A, Chargui R, Khomsi F, Mahjoub S, Slimene M, Ben Dhiab T, Hechiche M, Boussen H, Rahal K: Phyllodes tumors of the breast: a case series of 106 patients. Am J Surg; 2006 Aug;192(2):141-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phyllodes tumors of the breast: a case series of 106 patients.
  • BACKGROUND: Phyllodes tumors (PTs) of the breast are rare, and their prognosis and treatment are still subject of discussion.
  • According to criteria of Azzopardi and Salvadori, tumors were classified into 3 groups: benign (62 cases, 58.4%), borderline (16 cases, 15%), and malignant (28 cases, 26.4%).
  • Eighty-two patients (77.4%) were treated conservatively (62 benign, 11 borderline, and 9 malignant) and 24 (22.6%) by radical surgery (5 borderline and 19 malignant).
  • For malignant PTs treated by enucleation or local excision with or without reexcision of the tumor bed, the 5-year overall and disease-free survivals were 28.5% and 15.6% versus 72.7% and 73.6% when the surgery was radical (mastectomy with or without axillary dissection) (P = .12 and P = .0022).
  • The rate of recurrence was 12.2% (13) after a mean follow-up of 39 months (5 benign, 2 borderline, and 5 malignant).
  • In univariate analysis, age and recurrences are not of prognostic value for survival, whereas tumor size, histotype, necrosis, cytonuclear atypia, tumor margins, and number of mitosis were significant prognostic factors for survival.
  • CONCLUSION: According to our results, we recommend for malignant PT a simple mastectomy, whereas for borderline and benign PT, treatment is based rather on wide excision passing in healthy tissue.
  • [MeSH-major] Breast Neoplasms / diagnosis. Mastectomy / methods. Phyllodes Tumor / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Disease-Free Survival. Female. Follow-Up Studies. Humans. Mammography. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16860620.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Salem AM, Zohny SF, Abd El-Wahab MM, Hamdy R: Predictive value of osteocalcin and beta-CrossLaps in metastatic breast cancer. Clin Biochem; 2007 Nov;40(16-17):1201-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of osteocalcin and beta-CrossLaps in metastatic breast cancer.
  • OBJECTIVES: Assessment of the diagnostic value of serum CEA, CA 15.3, osteocalcin (OC) and beta-CrossLaps (beta-CTX) in the detection of metastatic breast cancer.
  • DESIGN AND METHODS: This study included 47 patients with breast cancer (20 non-metastatic breast cancer, 11 bone metastasis, 11 soft tissue metastasis, 5 bone plus soft tissue metastasis), 10 patients with benign breast lesions and 13 healthy volunteers.
  • RESULTS: CEA, CA 15.3, OC and beta-CTX median levels were higher in breast cancer patients compared to controls (p=0.006, 0.001, 0.004 and 0.038, respectively).
  • CONCLUSIONS: Combined use of OC and beta-CTX could be useful in early detection of bone metastatic breast cancer which might improve the outcome of the disease.
  • [MeSH-major] Breast Neoplasms / blood. Collagen / blood. Osteocalcin / blood. Peptide Fragments / blood
  • [MeSH-minor] Biomarkers, Tumor / blood. Bone Neoplasms / blood. Bone Neoplasms / secondary. Carcinoembryonic Antigen / blood. Egypt. Female. Humans. Middle Aged. Mucin-1 / blood. Predictive Value of Tests. ROC Curve. Soft Tissue Neoplasms / blood. Soft Tissue Neoplasms / secondary

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17889845.001).
  • [ISSN] 0009-9120
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Mucin-1; 0 / Peptide Fragments; 0 / glutamyl-lysyl-alanyl-histidyl-aspartyl-glycyl-glycyl-arginine; 104982-03-8 / Osteocalcin; 9007-34-5 / Collagen
  •  go-up   go-down


21. Behera MA, Dai Q, Garde R, Saner C, Jungheim E, Price TM: Progesterone stimulates mitochondrial activity with subsequent inhibition of apoptosis in MCF-10A benign breast epithelial cells. Am J Physiol Endocrinol Metab; 2009 Nov;297(5):E1089-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progesterone stimulates mitochondrial activity with subsequent inhibition of apoptosis in MCF-10A benign breast epithelial cells.
  • The effects of progesterone on breast epithelial cells remain poorly defined with observations showing both proliferative and antiproliferative effects.
  • The release of paracrine growth factors from nuclear receptor-positive cells has been postulated as a mechanism, since in vitro studies show a lack of growth effect by progesterone in breast epithelial cells lacking nuclear receptors.
  • This study examined possible nongenomic effects of progesterone in breast epithelia by using MCF-10A cells known to lack nuclear progesterone receptor expression.
  • Our study demonstrates a nongenomic action of progesterone on benign breast epithelial cells, resulting in enhanced cellular respiration and protection from apoptosis.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • Hazardous Substances Data Bank. CYCLOHEXIMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Cell Cardiol. 1995 Oct;27(10):2167-76 [8576933.001]
  • [Cites] Genes Dev. 1995 Sep 15;9(18):2266-78 [7557380.001]
  • [Cites] Breast Cancer Res Treat. 1997 Sep;45(2):121-33 [9342437.001]
  • [Cites] Exp Cell Res. 1997 Oct 10;236(1):223-30 [9344602.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):4987-91 [9371488.001]
  • [Cites] J Biol Chem. 1999 Apr 30;274(18):12567-75 [10212235.001]
  • [Cites] Breast Cancer Res Treat. 1999 Feb;53(3):217-27 [10369068.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Nov;97(3):278-88 [16154741.001]
  • [Cites] Dev Cell. 2005 Dec;9(6):843-54 [16326395.001]
  • [Cites] J Steroid Biochem Mol Biol. 2006 Feb;98(2-3):174-8 [16413775.001]
  • [Cites] J Biol Chem. 2006 Mar 3;281(9):5837-44 [16407197.001]
  • [Cites] J Steroid Biochem Mol Biol. 2006 Mar;98(4-5):218-27 [16466914.001]
  • [Cites] Carcinogenesis. 2006 May;27(5):925-35 [16361271.001]
  • [Cites] Apoptosis. 2006 Apr;11(4):473-85 [16532373.001]
  • [Cites] Biochim Biophys Acta. 2006 May-Jun;1757(5-6):509-17 [16829228.001]
  • [Cites] Maturitas. 2006 Jul 20;54(4):327-34 [16806749.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2006 Nov;129(1):77-83 [16460873.001]
  • [Cites] Mol Endocrinol. 2006 Dec;20(12):3146-64 [16959873.001]
  • [Cites] FEBS J. 2007 Mar;274(6):1393-418 [17302740.001]
  • [Cites] Endocrinology. 2007 Jun;148(6):2723-36 [17332059.001]
  • [Cites] Cell Prolif. 2007 Oct;40(5):721-40 [17877612.001]
  • [Cites] Biol Chem. 2007 Oct;388(10):1113-9 [17937626.001]
  • [Cites] Mitochondrion. 2007 Dec;7(6):399-401 [17881297.001]
  • [Cites] Methods. 2008 Mar;44(3):222-8 [18314052.001]
  • [Cites] Breast. 2008 Apr;17(2):172-9 [17928227.001]
  • [Cites] Cell Res. 2009 Jan;19(1):140-8 [19079362.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Dec;84(12):4559-65 [10599719.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):867-72 [10706096.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):936-43 [10706108.001]
  • [Cites] Oncology. 2000;59 Suppl 1:39-44 [11096355.001]
  • [Cites] Mol Endocrinol. 2001 Feb;15(2):255-70 [11158332.001]
  • [Cites] Mol Cell Endocrinol. 2001 Jun 20;179(1-2):97-103 [11420134.001]
  • [Cites] Endocrinology. 2002 Aug;143(8):3071-82 [12130573.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):93-105 [12160089.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):420-30 [12189384.001]
  • [Cites] Breast Cancer Res. 2002;4(5):187-90 [12223122.001]
  • [Cites] Mol Endocrinol. 2003 Jan;17(1):117-27 [12511611.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2231-6 [12574519.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2237-42 [12601167.001]
  • [Cites] Mol Cell Endocrinol. 2003 Feb 28;200(1-2):155-63 [12644308.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):25-30 [12650698.001]
  • [Cites] Biochim Biophys Acta. 2004 Jul 23;1658(1-2):141-7 [15282185.001]
  • [Cites] Proc Natl Acad Sci U S A. 1974 Aug;71(8):2942-5 [4528490.001]
  • [Cites] Nature. 1975 Feb 27;253(5494):746-7 [1113869.001]
  • [Cites] Cancer Res. 1978 Aug;38(8):2434-7 [667841.001]
  • [Cites] Exp Cell Res. 1988 Sep;178(1):143-53 [3409975.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] Mol Endocrinol. 1990 Dec;4(12):1833-40 [2082185.001]
  • [Cites] Cancer Res. 1994 Jan 15;54(2):340-3 [8275464.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3868-77 [8033109.001]
  • [Cites] J Exp Med. 1994 Sep 1;180(3):917-23 [8064240.001]
  • [Cites] Am J Obstet Gynecol. 1997 Jan;176(1 Pt 1):123-8 [9024102.001]
  • (PMID = 19690070.001).
  • [ISSN] 1522-1555
  • [Journal-full-title] American journal of physiology. Endocrinology and metabolism
  • [ISO-abbreviation] Am. J. Physiol. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / 1R03HD-052770-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Inhibitor of Differentiation Protein 1; 0 / Protein Synthesis Inhibitors; 0 / Receptors, Progesterone; 0 / Transforming Growth Factor beta1; 4G7DS2Q64Y / Progesterone; 8L70Q75FXE / Adenosine Triphosphate; 98600C0908 / Cycloheximide; EC 3.4.21.- / Kallikreins; EC 3.4.22.- / Caspases; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


22. Román-Díaz J, Alayón-Laguer D, Fernández Nelson M, Luis B, Caceres-Perkins W, Conde-Sterling D: Rare benign breast tumor. Bol Asoc Med P R; 2010 Apr-Jun;102(2):50-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare benign breast tumor.
  • We report the case of a female patient with an incidental finding at routine mammography evaluation which consisted of a benign spindle cell tumor, namely Breast Myofibroblastoma.
  • It is important to recognize the benign nature of this neoplasm to prevent extensive mutilating surgical procedures.
  • [MeSH-major] Breast Neoplasms / pathology. Neoplasms, Muscle Tissue / pathology
  • [MeSH-minor] Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20939206.001).
  • [ISSN] 0004-4849
  • [Journal-full-title] Boletín de la Asociación Médica de Puerto Rico
  • [ISO-abbreviation] Bol Asoc Med P R
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Puerto Rico
  •  go-up   go-down


23. Celis JE, Gromova I, Cabezón T, Gromov P, Shen T, Timmermans-Wielenga V, Rank F, Moreira JM: Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease. Mol Oncol; 2007 Dec;1(3):321-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease.
  • Recently, we presented evidence--based on the analysis of benign hyperproliferative lesions of the breast--for the presence of cells that express the stem cell marker cytokeratin (CK) 15 in combination with CK19, a protein widely expressed by mammary epithelial cells.
  • Here we report the finding of a subset of breast carcinomas characterized by expression of CK15.
  • CK15 expressing tumors constituted 5% (6 out of 120; 4 of ductal type and 2 of lobular type) of the high-risk breast carcinomas examined by gel-based proteomics and immunohistochemistry.
  • The remaining tumor was mainly composed of cells expressing both CK15 and CK19 (CK15+/CK19+), but it also contained invasive areas with cells expressing only one of these makers (CK15+/CK19- and CK15-/CK19+ cells).
  • To address the relationship between putative luminal progenitor/amplified CK15+ cells and malignant disease, and to determine whether cells/lesions lose expression of CK15 as a result of tumour initiation and/or progression, we searched among our sample set for carcinomas in which invasive tumor areas co-existed with non-malignant cells and hyperproliferative and known pre-malignant lesions.
  • Cells with a very similar phenotype to the CK15+/CK19+ progenitor cells were observed in a juvenile fibroadenoma as well as in the large collecting ducts of the breast.
  • The latter, however, expressed in addition CK14 and had a phenotype (CK15+/CK19+/CK14+/CK8+ (weak)/ER-/PgR-/AR-/CD44+ (weak)/CK17-/p63-/vimentin-/Ki67-/Bcl-2+/GATA-3-/p53-) that resembled that of the putative normal adult breast stem cells as inferred from published data.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Keratin-15 / metabolism. Precancerous Conditions / pathology. Stem Cells
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma / genetics. Carcinoma / metabolism. Carcinoma / pathology. Female. Fluorescent Antibody Technique, Direct. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness


24. Kim SH, Seo BK, Lee J, Kim SJ, Cho KR, Lee KY, Je BK, Kim HY, Kim YS, Lee JH: Correlation of ultrasound findings with histology, tumor grade, and biological markers in breast cancer. Acta Oncol; 2008;47(8):1531-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of ultrasound findings with histology, tumor grade, and biological markers in breast cancer.
  • BACKGROUND AND PURPOSE: Ultrasound has been used successfully to differentiate benign and malignant breast lesions.
  • The aim of this study was to investigate the correlation between ultrasound and prognostic indicators in breast cancer such as histological type, tumor grade, and biological markers.
  • MATERIALS AND METHODS: Ultrasound findings (shape, margin, orientation, boundary, echo pattern, posterior acoustic feature, and presence of calcifications) of 458 breast cancers were analyzed and correlated with the tumor type, tumor grade, and biological markers by univariate and multivariate logistic regression analyses.
  • CONCLUSION: Ultrasound pattern is correlated with tumor type, tumor grade, and biological markers in breast cancers and it may be useful for prediction of prognosis.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / pathology. Breast Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / secondary. Carcinoma, Ductal, Breast / ultrastructure. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / secondary. Carcinoma, Intraductal, Noninfiltrating / ultrastructure. Carcinoma, Lobular / pathology. Carcinoma, Lobular / secondary. Carcinoma, Lobular / ultrastructure. Diagnosis, Differential. Female. Humans. Lymphatic Metastasis. Middle Aged. Prognosis. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18607848.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


25. Anderson KS, Wong J, Vitonis A, Crum CP, Sluss PM, Labaer J, Cramer D: p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer. Cancer Epidemiol Biomarkers Prev; 2010 Mar;19(3):859-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This group included women subsequently diagnosed with invasive serous ovarian cancer (n = 60), nonserous ovarian cancers (n = 30), and women with benign disease (n = 30).
  • RESULTS: p53-AAb were detected in 25 of 60 (41.7%) of serous cases, 4 of 30 (13.3%) nonserous cases, 3 of 30 (10%) benign disease cases, and 10 of 120 (8.3%) controls (combined P = 0.0002).
  • p53-AAb did not significantly improve the detection of cases [area under the curve (AUC), 0.69] or the discrimination of benign versus malignant disease (AUC, 0.64) compared with CA 125 (AUC, 0.99) or HE4 (AUC, 0.98).
  • In multivariate analysis among cases, p53-AAb correlated only with a family history of breast cancer (P = 0.01).

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2872-81 [18843033.001]
  • [Cites] Clin Cancer Res. 2008 Sep 15;14(18):5785-93 [18794088.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):40-6 [18851871.001]
  • [Cites] Gynecol Oncol. 2009 Jul;114(1):12-7 [19398128.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):47-54 [19007974.001]
  • [Cites] Oncology. 1999 Nov;57(4):324-9 [10575320.001]
  • [Cites] Clin Biochem. 2000 Feb;33(1):53-62 [10693987.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1432-7 [10717627.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1777-88 [10766157.001]
  • [Cites] Br J Cancer. 2000 Nov;83(10):1338-43 [11044359.001]
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):189-93 [11161858.001]
  • [Cites] Cancer. 2003 Jan 15;97(2):389-404 [12518363.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):285-91 [12619114.001]
  • [Cites] Cancer Detect Prev. 2003;27(3):182-6 [12787724.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3940-7 [12975461.001]
  • [Cites] Cancer Immunol Immunother. 2003 Dec;52(12):715-38 [12920480.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5120-6 [14613989.001]
  • [Cites] J Proteome Res. 2004 Mar-Apr;3(2):261-7 [15113102.001]
  • [Cites] Dis Markers. 2004;20(2):53-70 [15322314.001]
  • [Cites] J Natl Cancer Inst. 1988 Apr 6;80(3):208-9 [3162284.001]
  • [Cites] J Immunol. 1991 Aug 15;147(4):1338-43 [1831223.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3439-42 [1373500.001]
  • [Cites] JAMA. 1993 Mar 3;269(9):1123-6 [8433467.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):70-8 [7799045.001]
  • [Cites] Cancer Detect Prev. 1995;19(2):151-5 [7750102.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1201-8 [8630898.001]
  • [Cites] Cancer. 1996 Nov 15;78(10):2146-52 [8918407.001]
  • [Cites] Gynecol Oncol. 1999 Jan;72(1):76-81 [9889034.001]
  • [Cites] Anticancer Res. 1999 Jan-Feb;19(1B):875-8 [10216509.001]
  • [Cites] Int J Gynecol Cancer. 2004 Nov-Dec;14(6):1086-96 [15571614.001]
  • [Cites] J Proteome Res. 2005 Jul-Aug;4(4):1123-33 [16083262.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1224-35 [16177248.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1181-90 [16424057.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):762-8 [16391298.001]
  • [Cites] Br J Cancer. 2006 Sep 4;95(5):627-33 [16880779.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • [Cites] Arthritis Res Ther. 2006;8(4):R109 [16846526.001]
  • [Cites] J Immunol. 2007 Mar 15;178(6):3831-6 [17339482.001]
  • [Cites] Ann Oncol. 2007 May;18(5):868-73 [17347129.001]
  • [Cites] Int J Cancer. 2007 Aug 1;121(3):606-14 [17415711.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4422-8 [17671125.001]
  • [Cites] Nat Med. 2007 Sep;13(9):1050-9 [17704786.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17494-9 [17954908.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6984-92 [18056174.001]
  • [Cites] Gynecol Oncol. 2007 Dec;107(3):526-31 [17920110.001]
  • [Cites] Dis Markers. 2007;23(5-6):397-410 [18057523.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):89-96 [18172257.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):764-71 [18245537.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1490-9 [18311903.001]
  • [Cites] PLoS One. 2008;3(7):e2633 [18612378.001]
  • [Cites] Gynecol Oncol. 2008 Sep;110(3):365-73 [18571704.001]
  • [Cites] Am J Surg Pathol. 2008 Nov;32(11):1667-74 [18769340.001]
  • (PMID = 20200435.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA117374-05; United States / NCI NIH HHS / CA / U01 CA117374; United States / NCI NIH HHS / CA / U01 CA086381-05; United States / NCI NIH HHS / CA / U01 CA086381; United States / NCI NIH HHS / CA / UO1 CA086381; United States / NCI NIH HHS / CA / CA117374-05; United States / NCI NIH HHS / CA / CA086381-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / Tumor Suppressor Protein p53; 0 / beta-Defensins
  • [Other-IDs] NLM/ NIHMS174572; NLM/ PMC2838192
  •  go-up   go-down


26. Tang HW, Luo MN, Li T, Pan L: Quantitative DNA imaging in breast tumor cells by a Hadamard transform fluorescence imaging microscope. Anal Sci; 2006 May;22(5):701-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative DNA imaging in breast tumor cells by a Hadamard transform fluorescence imaging microscope.
  • In this study, the high potential value of the microscope in biomedical analysis has been demonstrated by using it to evaluate the malignancy degree of thirty cases of human breast tumors based on the measurements of cellular DNA contents, with conclusions highly accordant with pathological diagnosis.
  • The microscope was also successfully applied to cellular morphological analysis, and it was demonstrated that a significant linear relationship exists between tumor nuclear DNA contents and the nuclear area, and malignant and benign tumors are significantly different in both DNA contents and nuclear area.
  • [MeSH-major] Breast Neoplasms / pathology. DNA, Neoplasm / analysis
  • [MeSH-minor] Female. Humans. Image Cytometry. Microscopy, Fluorescence. Ploidies. Sensitivity and Specificity. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770048.001).
  • [ISSN] 0910-6340
  • [Journal-full-title] Analytical sciences : the international journal of the Japan Society for Analytical Chemistry
  • [ISO-abbreviation] Anal Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


27. Sakamoto N, Tozaki M, Higa K, Tsunoda Y, Ogawa T, Abe S, Ozaki S, Sakamoto M, Tsuruhara T, Kawano N, Suzuki T, Yamashiro N, Fukuma E: Categorization of non-mass-like breast lesions detected by MRI. Breast Cancer; 2008;15(3):241-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Categorization of non-mass-like breast lesions detected by MRI.
  • BACKGROUND: Breast MR imaging has emerged as a highly sensitive modality for the imaging of breast tumors.
  • The purpose of this study was to analyze the features of non-mass-like breast lesions detected by MRI, and to establish a standardized method of interpretation to allow categorization of these lesions.
  • The presence of a ductal pattern was assessed in the enhancing lesions after the tumor distribution had been decided.
  • All lesions showing multiquadrant distribution, linear-nonspecific lesion, non-branching pattern with homogeneous and stippled internal architectures, and heterogeneous lesion without clustered ring enhancement were diagnosed as benign.
  • CONCLUSION: Non-mass-like breast lesions detected on MRI showing a clustered ring enhancement, a branching-ductal pattern, and clumped architecture should be evaluated further by biopsy (category 4), while lesions not showing these characteristics may be observed without unnecessary intervention (category 3a).
  • [MeSH-major] Breast Diseases / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Image Interpretation, Computer-Assisted. Mammography. Middle Aged. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18224381.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


28. Hsiao YH, Huang YL, Liang WM, Lin C, Kuo SJ, Chen DR: Characterization of benign and malignant solid breast masses: harmonic versus nonharmonic 3D power Doppler imaging. Ultrasound Med Biol; 2009 Mar;35(3):353-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of benign and malignant solid breast masses: harmonic versus nonharmonic 3D power Doppler imaging.
  • The aim of this study was to compare the diagnostic performance of nonharmonic ultrasound (US) and tissue harmonic imaging (THI) using three-dimensional (3D) power Doppler sonographic technique to classify benign and malignant breast tumors by vascularization.
  • All subjects with one or more breast masses were studied with 3D power Doppler US nonharmonic and harmonic technologies.
  • A total of 97 benign and 86 pathologically proven malignant breast tumor images were analyzed.
  • Three histogram indices, the vascularization index (VI), flow index (FI) and vascularization-flow index (VFI), on both nonharmonic and harmonic images were calculated for the intratumor and for shells with an outside thickness of 3 mm surrounding the breast lesion.
  • A multilayer perception (MLP) neural network classifier used the vascularity indices to determine whether the breast tumors are benign or malignant.
  • ROC curve analysis used overall age, volume, VI, FI and VFI for both intratumor and shells with an outside thickness of 3 mm surrounding the breast lesions in nonharmonic US and THI.
  • In conclusion, the performance of 3D power Doppler US with respect to the characterization of solid breast masses as benign or malignant was not significantly improved with tissue harmonic imaging.
  • [MeSH-major] Breast Neoplasms / ultrasonography
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Image Interpretation, Computer-Assisted / methods. Middle Aged. Neovascularization, Pathologic / ultrasonography. Neural Networks (Computer). Ultrasonography, Doppler / methods. Ultrasonography, Mammary / methods. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19041173.001).
  • [ISSN] 1879-291X
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


29. Zhou Y, Inaba S, Liu J: Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment. Int J Oncol; 2006 Jul;29(1):289-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment.
  • Anti-microtubule drugs that cause mitotic arrest and subsequent apoptosis of cancer cells are frequently used to treat breast cancer patients with advanced or metastatic diseases.
  • Our previous studies have demonstrated that the neuronal protein, synuclein-gamma (SNCG), plays oncogenic roles in breast carcinogenesis and is abnormally expressed at high levels in advanced and metastatic breast carcinomas but not expressed in normal or benign breast tissues.
  • In this study, we show that responses of 12 breast cancer cell lines to paclitaxel-induced mitotic arrest and cytotoxicity highly correlate with SNCG expression status.
  • Moreover, we demonstrate that down-regulation of SNCG expression directly increased the effectiveness of anti-microtubule drug-induced cytotoxicity in breast cancer cells without altering cell responses to doxorubicin.
  • These new findings suggest that SNCG expression in breast carcinomas is probably a causal factor contributing to the poor patient response to paclitaxel treatment.
  • [MeSH-major] Antimitotic Agents / pharmacology. Antineoplastic Agents, Phytogenic / pharmacology. Breast Neoplasms / metabolism. Neoplasm Proteins / metabolism. Paclitaxel / pharmacology. gamma-Synuclein / metabolism
  • [MeSH-minor] Antibiotics, Antineoplastic / pharmacology. Cell Line, Tumor. Cell Proliferation / drug effects. Doxorubicin / pharmacology. Drug Resistance, Neoplasm. Female. Gene Silencing. Humans. Inhibitory Concentration 50. Oncostatin M / pharmacology. RNA, Antisense / genetics. RNA, Antisense / metabolism. Time Factors. Transfection. Tumor Stem Cell Assay. Urea / analogs & derivatives. Urea / pharmacology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. UREA .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16773211.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / 3-bromopropionylamino benzoylurea; 0 / Antibiotics, Antineoplastic; 0 / Antimitotic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Neoplasm Proteins; 0 / RNA, Antisense; 0 / SNCG protein, human; 0 / gamma-Synuclein; 106956-32-5 / Oncostatin M; 80168379AG / Doxorubicin; 8W8T17847W / Urea; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


30. França SR, Caldas D, Alcebíades V 2nd, de Oliveira CA: [Mucoepidermoid carcinoma of the thyroid: a case report and literature review]. Arq Bras Endocrinol Metabol; 2006 Oct;50(5):968-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Carcinoma mucoepidermóide de tireóide: relato de caso e revisão da literatura.
  • The mucoepidermoid carcinoma is a neoplasia that usually occurs at salivary glands, breast, pancreas and gastrointestinal tract.
  • Although the majority of cases of mucoepidermoid carcinoma of the thyroid (MECT) show a benign evolution, this paper describes a patient with an aggressive tumor.
  • [MeSH-minor] Calcitonin / analysis. Female. Humans. Middle Aged. Mucins / metabolism. Neoplasm Recurrence, Local / pathology. Prognosis. Thyroid Gland / pathology. Thyroidectomy. Whole Body Imaging

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160225.001).
  • [ISSN] 0004-2730
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Mucins; 9007-12-9 / Calcitonin
  • [Number-of-references] 26
  •  go-up   go-down


31. Sotheran W, Domjan J, Jeffrey M, Wise MH, Perry PM: Phyllodes tumours of the breast--a retrospective study from 1982-2000 of 50 cases in Portsmouth. Ann R Coll Surg Engl; 2005 Sep;87(5):339-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phyllodes tumours of the breast--a retrospective study from 1982-2000 of 50 cases in Portsmouth.
  • These comprised 29 benign, 12 borderline and 9 malignant phyllodes tumours.
  • RESULTS: All benign phyllodes tumours were treated with breast-conserving surgery, these included 16 tumours over 40 mm.
  • Borderline and malignant lesions were treated by breast-conserving surgery or mastectomy.
  • Breast-conserving surgery appeared to be as effective as mastectomy.
  • Recurrence occurred in 1/29 benign tumours.
  • CONCLUSIONS: Breast-conserving surgery is the treatment of choice for all benign lesions.
  • [MeSH-major] Breast Neoplasms / surgery. Phyllodes Tumor / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / etiology. Neoplasm Recurrence, Local / pathology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16176692.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1963973
  •  go-up   go-down


32. Shaker OG, Ay El-Deen MA, Abd El-Rahim MT, Talaat RM: Gene expression of E-selectin in tissue and its protein level in serum of breast cancer patients. Tumori; 2006 Nov-Dec;92(6):524-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression of E-selectin in tissue and its protein level in serum of breast cancer patients.
  • AIMS AND BACKGROUND: This study aims to detect the expression of E-selectin in tissue and the serum level of its soluble form in patients with primary breast cancer and benign breast tumors and to correlate the results with the clinicopathological data of the subjects.
  • Group A comprised 30 patients with primary breast cancer, group B 9 patients with benign breast tumors, and group C 11 healthy control women undergoing reduction mammoplasty.
  • E-selectin gene expression was investigated in breast tissues by PCR techniques and soluble E-selectin was measured in sera by ELISA.
  • It was expressed in 61.5% of patients with grade 2 breast cancer and in 82.4% of patients with grade 3 breast cancer.
  • It was detected in 81.8% of patients with node-positive primary breast cancer and in 50% of patients with node-negative cancer.
  • E-selectin was found on the membranes of peritumoral endothelial cells while it was not found on breast epithelial cells.
  • They increased significantly with increasing breast cancer stage (P < 0.001) and were significantly higher in patients with lymph node involvement than in patients without node involvement (P < 0.001).
  • CONCLUSIONS: The studied marker showed associations with established prognostic parameters such as lymph node involvement and histological tumor grade.
  • E-selectin can be regarded as a promising strategy in improving tumor therapy.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. E-Selectin / metabolism. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Adolescent. Adult. Aged. Breast Diseases / metabolism. Case-Control Studies. Enzyme-Linked Immunosorbent Assay. Female. Humans. In Situ Hybridization. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Predictive Value of Tests. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17260494.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / E-Selectin
  •  go-up   go-down


33. Stojadinovic A, Hooke JA, Shriver CD, Nissan A, Kovatich AJ, Kao TC, Ponniah S, Peoples GE, Moroni M: HYOU1/Orp150 expression in breast cancer. Med Sci Monit; 2007 Nov;13(11):BR231-239
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HYOU1/Orp150 expression in breast cancer.
  • Preliminary studies demonstrated increased HYOU1/Orp150 expression in prostate, bladder and invasive breast cancer.
  • This study further evaluates HYOU1/Orp150 expression in different stages of breast cancer such as benign, pre-malignant and malignant lesions, and correlates it with clinical and pathological data.
  • MATERIAL/METHODS: Sixty-six paraffin-embedded breast tissue sections were stained by immunohistochemistry using HYOU1/Orp150 antibody.
  • RESULTS: There was a small but significant increase (P<0.01) in HYOU1/Orp150 expression as the tumor transformed from benign (mean 1.52+/-0.12) to ductal carcinoma in situ (mean 2.05+/-0.14) and invasive carcinoma (mean 2.1+/-0.17).
  • HYOU1/Orp150 was partially lost in the benign tissue adjacent to purely invasive cancer (0.88+/-0.22) and it was less (P=0.046) than what was found in benign only lesions (1.52+/-0.12) or in benign components adjacent to DCIS (1.47+/-0.16).
  • Overexpression of HYOU1/Orp150 was associated with tumor lymph node involvement, presence of lymphovascular invasion, and absence of estrogen receptor expression (P<0.01).
  • CONCLUSIONS: HYOU1/Orp150 is overexpressed in some invasive breast cancers and its overexpression appears to be associated with indicators of poor prognosis.
  • [MeSH-major] Breast Neoplasms / metabolism. Proteins / metabolism
  • [MeSH-minor] Breast Diseases / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Female. HSP70 Heat-Shock Proteins. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Retrospective Studies


34. Medved M, Newstead GM, Fan X, Du YP, Olopade OI, Shimauchi A, Zamora MA, Karczmar GS: Fourier component imaging of water resonance in the human breast provides markers for malignancy. Phys Med Biol; 2009 Oct 7;54(19):5767-79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fourier component imaging of water resonance in the human breast provides markers for malignancy.
  • The purpose of this paper is to demonstrate that voxels with inhomogeneously broadened water resonances, as revealed by high spectral and spatial resolution (HiSS) MRI, correlate with underlying tumor pathology findings, and thus carry diagnostically useful information.
  • Thirty-four women with mammographically suspicious breast lesions were imaged at 1.5 T, using high-resolution echo-planar spectroscopic imaging.
  • Inhomogeneously broadened clusters were found significantly more frequently in malignant than in benign lesions.
  • A larger percentage of broadened cluster voxels were found inside the malignant versus benign lesions.
  • The high statistical significance for separation of benign and malignant lesions was robust over a large range of post-processing parameters, with a maximum ROC area under curve of 0.83.
  • In the human breast, an inhomogeneously broadened water resonance can serve as a correlate marker for malignancy and is likely to reflect the underlying anatomy or physiology.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Water .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Magn Reson Med. 2000 May;43(5):633-9 [10800026.001]
  • [Cites] Magn Reson Med. 2009 Feb;61(2):291-8 [19165878.001]
  • [Cites] Radiology. 2000 Aug;216(2):545-53 [10924584.001]
  • [Cites] NMR Biomed. 2000 Nov;13(7):392-7 [11114062.001]
  • [Cites] Eur Radiol. 2001;11(4):531-46 [11354744.001]
  • [Cites] Neuroradiology. 2001 May;43(5):364-9 [11396739.001]
  • [Cites] NMR Biomed. 2002 Feb;15(1):28-36 [11840550.001]
  • [Cites] Acad Radiol. 2002 May;9 Suppl 1:S115-8 [12019844.001]
  • [Cites] AJR Am J Roentgenol. 2002 Jun;178(6):1411-7 [12034608.001]
  • [Cites] Radiology. 2002 Aug;224(2):577-85 [12147859.001]
  • [Cites] Acad Radiol. 2002 Aug;9 Suppl 2:S352-4 [12188272.001]
  • [Cites] J Magn Reson Imaging. 2002 Nov;16(5):547-52 [12412031.001]
  • [Cites] Ann N Y Acad Sci. 2002 Dec;980:95-115 [12594084.001]
  • [Cites] J Magn Reson Imaging. 2003 Oct;18(4):442-8 [14508781.001]
  • [Cites] J Magn Reson Imaging. 2004 Jul;20(1):56-65 [15221809.001]
  • [Cites] Magn Reson Med. 2004 Jul;52(1):193-6 [15236386.001]
  • [Cites] Magn Reson Med. 1984 Sep;1(3):370-86 [6571566.001]
  • [Cites] Biophys J. 1987 Oct;52(4):611-6 [3676441.001]
  • [Cites] Radiology. 1997 Jul;204(1):272-7 [9205259.001]
  • [Cites] Magn Reson Med. 1997 Jul;38(1):27-32 [9211376.001]
  • [Cites] Acad Radiol. 1998 Apr;5(4):269-75 [9561260.001]
  • [Cites] Radiology. 2006 Jan;238(1):42-53 [16373758.001]
  • [Cites] Phys Med Biol. 2008 Sep 7;53(17):4509-22 [18677038.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):481-8 [10802376.001]
  • (PMID = 19741276.001).
  • [ISSN] 1361-6560
  • [Journal-full-title] Physics in medicine and biology
  • [ISO-abbreviation] Phys Med Biol
  • [Language] ENG
  • [Grant] None / None / / P50 CA125183-01; United States / NCI NIH HHS / CA / P50 CA125183; United States / NCI NIH HHS / CA / R01 CA133490; United States / NCI NIH HHS / CA / 1R01CA78803; United States / NCI NIH HHS / CA / 1P50CA125183-01; United States / NIBIB NIH HHS / EB / R01 EB003108-03; United States / NCI NIH HHS / CA / P50 CA125183-01; United States / NCI NIH HHS / CA / R01 CA078803; United States / NCI NIH HHS / CA / P50 CA125183-03; United States / NIBIB NIH HHS / EB / EB003108-03; United States / NIBIB NIH HHS / EB / R01 EB003108; United States / NCI NIH HHS / CA / CA078803-07; United States / NCI NIH HHS / CA / R01 CA078803-07; United States / NIBIB NIH HHS / EB / 5R01EB003108-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 059QF0KO0R / Water
  • [Other-IDs] NLM/ NIHMS226672; NLM/ PMC2941263
  •  go-up   go-down


35. Harman SM, Gucciardo F, Heward CB, Granstrom P, Barclay-White B, Rogers LW, Ibarra JA Jr: Discrimination of breast cancer by anti-malignin antibody serum test in women undergoing biopsy. Cancer Epidemiol Biomarkers Prev; 2005 Oct;14(10):2310-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discrimination of breast cancer by anti-malignin antibody serum test in women undergoing biopsy.
  • To objectively assess accuracy of this test for discrimination of breast cancer, we studied a series of women undergoing core breast biopsy.
  • SUBJECTS AND METHODS: Seventy-one core-needle breast biopsies were classified as malignant, suspicious, or benign by two independent pathologists blinded to AMAS results.
  • RESULTS: Biopsies were read as 42 (59%) benign, 12 (17%) suspicious, and 17 (24%) malignant.
  • CONCLUSIONS: The AMAS test discriminates suspicious and malignant from benign lesions, but sensitivity is insufficient to identify patients to be spared biopsy and false-positive rates are too high for population screening.
  • [MeSH-major] Biomarkers, Tumor / isolation & purification. Breast Neoplasms / pathology. Neoplasm Proteins
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Anti-Idiotypic / blood. Biopsy, Needle. False Positive Reactions. Female. Humans. Middle Aged. ROC Curve. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16214910.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 63626-45-9 / malignin
  •  go-up   go-down


36. Richards T, Hunt A, Courtney S, Umeh H: Nipple discharge: a sign of breast cancer? Ann R Coll Surg Engl; 2007 Mar;89(2):124-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nipple discharge: a sign of breast cancer?
  • INTRODUCTION: Nipple discharge is regarded a sign of breast cancer.
  • Type of discharge and cytology are unreliable for diagnosis.
  • Most malignant cases have a detectable breast mass.
  • The aim of this study was to assess the association between nipple discharge and breast cancer.
  • Histopathology reported duct ectasia in 59 patients and benign ductal papilloma in 25.
  • CONCLUSIONS: Nipple discharge alone is not usually a sign of breast cancer.
  • [MeSH-major] Biomarkers, Tumor / secretion. Breast Neoplasms / diagnosis. Exudates and Transudates / secretion. Nipples / secretion
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 1989 Nov-Dec;13(6):736-42 [2696228.001]
  • [Cites] Br J Clin Pract Suppl. 1989 Nov;68:54-7; discussion 67-72 [2488566.001]
  • [Cites] BMJ. 1994 Oct 8;309(6959):946-9 [7755694.001]
  • [Cites] Br J Surg. 1960 Mar;47:472-7 [13830762.001]
  • [Cites] Cytopathology. 2004 Dec;15(6):326-30 [15606366.001]
  • [Cites] Eur J Surg Oncol. 2005 Feb;31(1):3-8 [15642418.001]
  • [Cites] Ann Surg Oncol. 2005 Jul;12(7):546-51 [15889216.001]
  • [Cites] Curr Treat Options Oncol. 2002 Apr;3(2):157-61 [12057078.001]
  • [Cites] Breast J. 2004 Mar-Apr;10(2):111-7 [15009037.001]
  • [Cites] Surgery. 2004 Oct;136(4):780-5 [15467662.001]
  • [Cites] Br J Surg. 1968 Jul;55(7):530-5 [5663437.001]
  • [Cites] Br J Surg. 1983 Oct;70(10):601-3 [6684964.001]
  • [Cites] Am J Surg. 1985 Jun;149(6):789-92 [4040331.001]
  • [Cites] Hum Pathol. 1985 Aug;16(8):796-807 [2991111.001]
  • [Cites] Lancet. 1989 Jul 1;2(8653):25-7 [2567800.001]
  • (PMID = 17346403.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC1964556
  •  go-up   go-down


37. Salhab M, Singh-Ranger G, Mokbel R, Jouhra F, Jiang WG, Mokbel K: Cyclooxygenase-2 mRNA expression correlates with aromatase expression in human breast cancer. J Surg Oncol; 2007 Oct 1;96(5):424-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 mRNA expression correlates with aromatase expression in human breast cancer.
  • INTRODUCTION: The cyclooxygenase-2 (COX-2), responsible for the conversion of arachidonic acid into prostaglandin (PG) E2, is known to increase intracellular cAMP and estrogen production in malignant breast tissue.
  • The aromatase enzyme complex is responsible for local production of estrogens in breast cancer.
  • The aim of this study was to examine the relationship between COX-2 and aromatase mRNA expression in human breast cancer.
  • METHODS: A total of 160 breast samples (127 tumor tissues and 33 normal tissues) were analyzed.
  • RESULTS: Levels of expression of COX-2/CK19 of both benign and malignant tissues were positively correlated with aromatase/CK19 transcript levels (correlation coefficient = +0.536, P < 0.0001).
  • CONCLUSION: This study demonstrates a strong positive relationship between COX-2 and aromatase mRNA expression, and lends further support to the hypothesis that COX-2 is an upregulator of aromatase in breast tissue.
  • [MeSH-major] Aromatase / metabolism. Breast Neoplasms / metabolism. Cyclooxygenase 2 / metabolism. RNA, Messenger / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Breast / metabolism. Female. Humans. Keratin-19 / metabolism. Polymerase Chain Reaction. Up-Regulation

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17657731.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-19; 0 / RNA, Messenger; EC 1.14.14.1 / Aromatase; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


38. Königsberg R, Rögelsperger O, Jäger W, Thalhammer T, Klimpfinger M, De Santis M, Hudec M, Dittrich C: Cell cycle dysregulation influences survival in high risk breast cancer patients. Cancer Invest; 2008 Aug;26(7):734-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell cycle dysregulation influences survival in high risk breast cancer patients.
  • Recent immunohistological studies suggested that dysregulation of cyclin A, cyclin D, cyclin E, p16(ink4), p21(waf1/cip1), and p27(kip1) are of prognostic value in patients with breast cancer.
  • Our study represents the first comprehensive immunohistochemical cell cycle marker analysis for cdc25A, cyclin A, cyclin D, cyclin E, p16(ink4), p21(waf1/cip1), p27(kip1), and pRb in tumor tissue and adjacent benign breast tissue from 69 primarily untreated breast cancer patients.
  • RESULTS: Sixty-nine patients with untreated, invasive breast cancer (n = 69) were divided into a low/ intermediate and a high risk group according to the St. Gallen 2005 consensus conference.
  • A subgroup of high risk breast cancer patients characterized in addition by overexpression of cdc25A, cyclin A, cyclin E, p16(ink4a), and p27(kip1) experienced a shortened mean survival of 222.03, 235.71, 257.25, 239.18, and 261.94 weeks, respectively.
  • Regarding benign breast tissue adjacent to breast cancer tissue, 59.4% of the patients investigated overexpressed cdc25A, 23.2% overexpressed pRb, and 63.2% exerted dysregulation of p27(kip1) while they proved to be negative for immunohistochemical staining regarding all other markers tested.
  • CONCLUSION: The immunohistological analyses of cdc25A, cyclin A, cyclin E, p16(ink4a), and p27(kip1) have the potential for further refining the risk assessment in patients with untreated breast cancer who belong to the high risk category defined according to the St. Gallen 2005 consensus conference.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / chemistry. Breast Neoplasms / mortality. Cell Cycle. Cell Cycle Proteins / analysis. Cell Proliferation
  • [MeSH-minor] Adult. Cyclin A / analysis. Cyclin D. Cyclin E / analysis. Cyclin-Dependent Kinase Inhibitor p16 / analysis. Cyclin-Dependent Kinase Inhibitor p21 / analysis. Cyclin-Dependent Kinase Inhibitor p27. Cyclins / analysis. Disease-Free Survival. Female. Humans. Immunohistochemistry. Intracellular Signaling Peptides and Proteins / analysis. Kaplan-Meier Estimate. Neoplasm Invasiveness. Proportional Hazards Models. Retinoblastoma Protein / analysis. Retrospective Studies. Risk Assessment. Treatment Outcome. cdc25 Phosphatases / analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18665474.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / CDKN1B protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin A; 0 / Cyclin D; 0 / Cyclin E; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Retinoblastoma Protein; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 3.1.3.48 / CDC25A protein, human; EC 3.1.3.48 / cdc25 Phosphatases
  •  go-up   go-down


39. Paulino AC, Fowler BZ: Secondary neoplasms after radiotherapy for a childhood solid tumor. Pediatr Hematol Oncol; 2005 Mar;22(2):89-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary neoplasms after radiotherapy for a childhood solid tumor.
  • This study was conducted to determine the outcome of patients who develop a second neoplasm after radiotherapy (RT) for a childhood solid tumor.
  • From 1956 to 1998, 429 children with a malignant solid tumor were treated at a single radiation oncology facility.
  • The medical records and radiotherapy charts were reviewed to determine if the patient developed a secondary neoplasm after treatment for malignancy.
  • Twenty-three (5.4%) patients developed a secondary neoplasm.
  • There were 14 malignant neoplasms in 13 (3.0%) and 14 benign neoplasms in 11 patients (2.6%).
  • The types of initial solid tumors treated with RT were Ewing sarcoma in 6, Wilms tumor in 6, medulloblastoma in 5, neuroblastoma in 3, and other in 3.
  • For the 14 malignant neoplasms, the median time interval from initial tumor to second malignancy was 10.1 years.
  • The 14 second malignant neoplasms (SMN) were osteosarcoma in 3, breast carcinoma in 2, melanoma in 2, malignant fibrous histiocytoma in 1, dermatofibrosarcoma in 1, leiomyosarcoma in 1, mucoepidermoid carcinoma in 1, colon cancer in 1, chronic myelogenous leukemia in 1, and basal cell carcinoma in 1.
  • The 5- and 10-year overall survival rate after diagnosis of an SMN was 69.2%; it was 70% for children with a SMN at the edge or inside the RT field and 66.7% for those outside of the RT field.
  • The 14 benign neoplasms appeared at a median time of 16.9 years and included cervical intraepithelial neoplasia in 3, osteochondroma in 3, thyroid adenoma in 1, duodenal adenoma in 1, lipoma in 1, cherry angioma in 1, uterine leiomyoma in 1, ovarian cystadenofibroma in 1, and giant cell tumor in 1.
  • Only 5 (36%) of the 14 benign tumors occurred in the RT field, with osteochondroma being the most common.
  • More than two-thirds of children with a radiation-induced malignancy are alive 10 years after the diagnosis of a SMN.
  • [MeSH-minor] Adolescent. Adult. Cause of Death. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Male. Radiation Dosage. Retrospective Studies. Survival Rate


40. Makkat S, Luypaert R, Sourbron S, Stadnik T, De Mey J: Quantification of perfusion and permeability in breast tumors with a deconvolution-based analysis of second-bolus T1-DCE data. J Magn Reson Imaging; 2007 Jun;25(6):1159-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantification of perfusion and permeability in breast tumors with a deconvolution-based analysis of second-bolus T1-DCE data.
  • PURPOSE: To test the feasibility of using a second-bolus injection, added to a routine breast MRI examination, to measure regional perfusion and permeability in human breast tumors.
  • MATERIALS AND METHODS: In 30 patients with breast tumors, first a routine whole-breast T1-DCE sequence was applied, and the slice where the lesion enhanced maximally was located.
  • A pixel-by-pixel model-independent deconvolution of the relative signal enhancement was performed to estimate the tumor blood flow (TBF), tumor volume of distribution (TVD), mean transit time (MTT), extraction flow product (EF), and extraction fraction (E).
  • RESULTS: In the malignant tumors, the parametric maps clearly delineated tumors from the breast tissue and enabled visualization of the heterogeneity.
  • The deconvolution analysis provided objective parametric maps of tumor perfusion with a mean TBF (84 +/- 48 mL/100 mL/minute) in malignant tumors in the high range of literature values.
  • CONCLUSION: In terms of these perfusion values, our method appears promising to quantitatively characterize tumor pathophysiology.
  • However, the number of patients was limited, and the separation between malignant and benign groups was not clear-cut.
  • Additional parameters generated through compartment modeling may improve the tumor differentiation.
  • [MeSH-major] Breast Neoplasms / blood supply. Breast Neoplasms / pathology. Contrast Media / pharmacokinetics. Gadolinium DTPA / pharmacokinetics. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Feasibility Studies. Female. Humans. Image Processing, Computer-Assisted. Injections. Middle Aged. Regional Blood Flow. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17520720.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


41. Baltzer PA, Benndorf M, Dietzel M, Gajda M, Camara O, Kaiser WA: Sensitivity and specificity of unenhanced MR mammography (DWI combined with T2-weighted TSE imaging, ueMRM) for the differentiation of mass lesions. Eur Radiol; 2010 May;20(5):1101-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: This study was performed to assess the sensitivity and specificity for malignant and benign mass lesions of a diagnostic approach combining DWI with T2-weighted images (unenhanced MR mammography, ueMRM) and compare the results with contrast-enhanced MR mammography (ceMRM).
  • MATERIALS AND METHODS: Consecutive patients undergoing histopathological verification of mass lesions after MR mammography without prior breast interventions (contrast-enhanced T1-weighted, T2-weighted and DWI sequences) were eligible for this retrospective investigation.
  • RESULTS: This study examined 81 lesions (27 benign, 54 malignant).
  • Tumor visibility was worse using ueMRM for both benign (P < 0.001) and malignant lesions (P = 0.004).
  • [MeSH-major] Breast Neoplasms / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Contrast Media. Diagnosis, Differential. Diffusion Magnetic Resonance Imaging / methods. Female. Humans. Middle Aged. ROC Curve. Retrospective Studies. Sensitivity and Specificity. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Imaging. 2006 Sep 13;6:135-43 [17015238.001]
  • [Cites] J Magn Reson Imaging. 2006 Aug;24(2):319-24 [16786565.001]
  • [Cites] Eur Radiol. 2007 Oct;17(10):2646-55 [17356840.001]
  • [Cites] Magn Reson Med Sci. 2007;6(1):21-7 [17510539.001]
  • [Cites] Nephrol Dial Transplant. 2009 Mar;24(3):856-63 [18952698.001]
  • [Cites] AJR Am J Roentgenol. 2002 Jul;179(1):171-8 [12076929.001]
  • [Cites] Eur Radiol. 2009 Jul;19(7):1612-20 [19288109.001]
  • [Cites] J Magn Reson Imaging. 2002 Aug;16(2):172-8 [12203765.001]
  • [Cites] Lancet. 2005 May 21-27;365(9473):1769-78 [15910949.001]
  • [Cites] Rofo. 2005 Jun;177(6):818-27 [15902631.001]
  • [Cites] Magn Reson Med Sci. 2005;4(1):35-42 [16127252.001]
  • [Cites] Magn Reson Imaging. 2005 Jun;23(5):685-9 [16051044.001]
  • [Cites] AJR Am J Roentgenol. 2005 Oct;185(4):964-70 [16177416.001]
  • [Cites] BMJ. 1994 Jun 11;308(6943):1552 [8019315.001]
  • [Cites] J Magn Reson Imaging. 2009 May;29(5):1080-4 [19388115.001]
  • [Cites] J Comput Assist Tomogr. 2002 Nov-Dec;26(6):1042-6 [12488758.001]
  • [Cites] Stroke. 2002 Jul;33(7):1799-802 [12105356.001]
  • [Cites] Radiology. 2007 Aug;244(2):356-78 [17641361.001]
  • [Cites] Radiology. 2007 Sep;244(3):672-91 [17709824.001]
  • [Cites] Radiat Med. 2008 Jan;26(1):15-20 [18236129.001]
  • [Cites] Ai Zheng. 2007 Feb;26(2):168-71 [17298747.001]
  • [Cites] Korean J Radiol. 2007 Sep-Oct;8(5):390-6 [17923781.001]
  • [Cites] Neuroradiology. 2003 Sep;45(9):592-7 [12923668.001]
  • [Cites] Magn Reson Med Sci. 2004 Jul 15;3(2):79-85 [16093623.001]
  • [Cites] J Comput Assist Tomogr. 2005 Sep-Oct;29(5):644-9 [16163035.001]
  • [Cites] Eur J Radiol. 2008 May;66(2):160-7 [18358659.001]
  • [Cites] Magn Reson Med Sci. 2008;7(1):23-9 [18460845.001]
  • [Cites] Breast Cancer. 2008;15(3):212-7 [18491206.001]
  • [Cites] Acad Radiol. 2007 Sep;14(9):1077-83 [17707315.001]
  • [Cites] AJR Am J Roentgenol. 2006 Aug;187(2):330-7 [16861534.001]
  • (PMID = 19936758.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


42. Ferreira M, Albarracin CT, Resetkova E: Pseudoangiomatous stromal hyperplasia tumor: a clinical, radiologic and pathologic study of 26 cases. Mod Pathol; 2008 Feb;21(2):201-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudoangiomatous stromal hyperplasia tumor: a clinical, radiologic and pathologic study of 26 cases.
  • In one patient (4%), an invasive ductal carcinoma was present within the pseudoangiomatous stromal hyperplasia tumor.
  • We found associated benign epithelial lesions in eight patients (31%) and/or gynecomastia-like changes in 17 patients (65%).
  • [MeSH-major] Breast / pathology. Breast Diseases / pathology
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Breast Neoplasms / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Female. Humans. Hyperplasia / pathology. Mammography. Middle Aged. Premenopause. Retrospective Studies. Stromal Cells / pathology. Ultrasonography, Mammary

  • Genetic Alliance. consumer health - Pseudoangiomatous stromal hyperplasia.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18084246.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


43. Hino N, Nakagawa Y, Ikushima Y, Yoshida M, Tsuyuguchi M: A case of a giant phyllodes tumor of the breast with hypoglycemia caused by high-molecular-weight insulin-like growth factor II. Breast Cancer; 2010 Apr;17(2):142-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of a giant phyllodes tumor of the breast with hypoglycemia caused by high-molecular-weight insulin-like growth factor II.
  • We report the case of a patient who presented with hypoglycemia associated with a giant breast mass and presence of serum high-molecular-weight insulin-like growth factor II (big IGF-II).
  • In July 2005, a 49-year-old woman was admitted because of delirium, transient loss of consciousness, and a giant mass of about 28 cm in diameter on the right breast.
  • Because we suspected that the big IGF-II was produced by the breast tumor and was likely the cause of the hypoglycemia, a mastectomy was performed.
  • A histological examination determined that the mass was a benign phyllodes tumor.
  • We suspected that the patient had non-islet cell tumor hypoglycemia (NICTH), but the behavioral symptoms of the hypoglycemia caused by NICTH were similar to some mental diseases, which made diagnosis based on the behavior alone difficult.
  • We suggest that co-occurrence of symptoms such as recent appearance of mental disease-like behavior, hypoglycemia, and giant breast tumor may help diagnose NICTH caused by big IGF-II.
  • [MeSH-major] Breast Neoplasms / etiology. Hypoglycemia / etiology. Insulin-Like Growth Factor II / metabolism. Phyllodes Tumor / etiology
  • [MeSH-minor] Blood Glucose / metabolism. Blotting, Western. Female. Humans. Insulin / metabolism. Middle Aged. Molecular Weight. Tomography, X-Ray Computed


44. Kawai K, Uetsuka K, Doi K, Nakayama H: The activity of matrix metalloproteinases (MMPS) and tissue inhibitors of metalloproteinases (TIMPs) in mammary tumors of dogs and rats. J Vet Med Sci; 2006 Feb;68(2):105-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We conducted zymography for detecting the activity of matrix metalloproteinases (MMPs) and reverse zymography for the activity of tissue inhibitors of metalloproteinases (TIMPs) in canine spontaneous and rat 7, 12-dimethylbenz(a)anthracene (DMBA)-induced mammary tumor tissues.
  • The activities of MMPs were significantly higher in malignant tissues than in benign ones of canine tumors, whereas the activity of only MMP-2 was higher in both benign and malignant rat tumors compared to normal tissues.
  • There were no differences of MMPs activities between benign and malignant rat tumors.
  • The activities were higher in malignant tissues than in benign ones of dogs, and higher in tumor tissues than in normal mammary tissues of rats.
  • The results of film in situ zymography for tissue localization of gelatinolytic activity showed that the digested area was more extended in malignant tumors than in benign ones of dogs.
  • However, the area was similarly extended in both benign and malignant rat tumors.
  • These results may indicate that the canine spontaneous malignant mammary tumors possess more aggressive nature than the rat chemically induced counterpart, resulting from the high level of MMPs and low level of TIMPs activities of the tumor tissues.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16520530.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Tissue Inhibitor of Metalloproteinases; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


45. Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, Clemons MJ: Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol; 2009 Sep;20(9):1499-504
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?
  • BACKGROUND: Decisions about systemic treatment of women with metastatic breast cancer are often based on estrogen receptor (ER), progesterone receptor (PgR), and Her2 status of the primary tumor.
  • This study prospectively investigated concordance in receptor status between primary tumor and distant metastases and assessed the impact of any discordance on patient management.
  • RESULTS: Forty women were enrolled; 35 of them underwent biopsy, yielding 29 samples sufficient for analysis; 3/29 biopsies (10%) showed benign disease.
  • CONCLUSIONS: This prospective study demonstrates the presence of substantial discordance in receptor status between primary tumor and metastases, which led to altered management in 20% of cases.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 2004 Nov-Dec;24(6):4205-10 [15739264.001]
  • [Cites] Jpn J Cancer Res. 1998 Jan;89(1):27-32 [9510472.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2469-76 [15753463.001]
  • [Cites] Med Hypotheses. 2005;64(6):1182-7 [15823713.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):257-63 [15952182.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4801-7 [17050865.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):118-45 [17159189.001]
  • [Cites] Anticancer Res. 2009 May;29(5):1557-62 [19443366.001]
  • [Cites] J Clin Pathol. 2000 Feb;53(2):125-30 [10767828.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3427-32 [12429630.001]
  • [Cites] J Pathol. 2004 Aug;203(4):918-26 [15258994.001]
  • [Cites] Am J Surg. 1979 Feb;137(2):260-2 [426187.001]
  • [Cites] Cancer. 1980 Feb 15;45(4):792-4 [7357496.001]
  • [Cites] Cancer Res. 1983 Jan;43(1):413-6 [6847780.001]
  • [Cites] Cancer. 1983 Aug 1;52(3):479-85 [6861087.001]
  • [Cites] Cancer Res. 1984 Feb;44(2):836-40 [6692382.001]
  • [Cites] Eur J Cancer Clin Oncol. 1984 Aug;20(8):1011-8 [6540683.001]
  • [Cites] Eur J Cancer Clin Oncol. 1987 Jun;23(6):819-26 [3653198.001]
  • [Cites] Pathol Res Pract. 1989 Dec;185(6):856-9 [2616369.001]
  • [Cites] Br J Cancer. 1990 Jun;61(6):877-80 [2372489.001]
  • [Cites] J Surg Oncol. 1994 Oct;57(2):71-7 [7934066.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3331-8 [7614468.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2584-9 [8823339.001]
  • [Cites] Breast Cancer Res Treat. 2005 Mar;90(1):65-70 [15770528.001]
  • (PMID = 19299408.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2731014
  •  go-up   go-down


46. Blum A, Hartmann KW, Rütten A: [Brownish coloration of the left nipple in a 60-year-old woman]. Hautarzt; 2010 Jan;61(1):64-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Bräunliche Verfärbung der linken Brustwarze bei einer 60-jährigen Patientin.
  • We report on a 60-year-old woman in whom this diagnosis was made based on clinical findings, dermoscopy, histology and immunohistology.
  • Circumscribed pigmentation of the nipple includes a wide spectrum of benign and malignant differential diagnostic considerations.
  • Dermoscopy can enhance the clinical diagnosis.
  • Pagetoid intraepithelial cells of a melanocytic tumor are positive for S100, HMB45 or melan A, but not for cytokeratins.
  • Intraepithelial tumor cells of Paget disease are positive for cytokeratin 7.
  • [MeSH-major] Erythema / diagnosis. Erythema / etiology. Nipples / pathology. Paget's Disease, Mammary / complications. Paget's Disease, Mammary / diagnosis
  • [MeSH-minor] Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast J. 2009 Jul-Aug;15(4):420-1 [19470138.001]
  • [Cites] Am J Dermatopathol. 2002 Jun;24(3):189-98 [12140433.001]
  • [Cites] Br J Dermatol. 1998 Aug;139(2):287-90 [9767245.001]
  • [Cites] J Am Acad Dermatol. 1994 Dec;31(6):1058-60 [7962760.001]
  • [Cites] Radiographics. 2009 Mar-Apr;29(2):509-23 [19325062.001]
  • [Cites] J Am Acad Dermatol. 2004 Oct;51(4):664-5 [15455482.001]
  • [Cites] Dermatol Surg. 2006 Jul;32(7):949-54 [16875480.001]
  • [Cites] Histopathology. 2009 Apr;54(5):614-7 [19413640.001]
  • [Cites] Dermatology. 2007;214(1):3-5 [17191039.001]
  • [Cites] Arch Dermatol. 2007 Jun;143(6):752-4 [17576941.001]
  • [Cites] Am J Dermatopathol. 2009 May;31(3):223-6 [19384061.001]
  • [Cites] Dermatol Surg. 2008 Aug;34(8):1101-3 [18462414.001]
  • [Cites] Clin Exp Dermatol. 2009 Jan;34(1):36-8 [18627392.001]
  • [Cites] Hautarzt. 1992 Jan;43(1):28-31 [1319418.001]
  • [Cites] J Am Acad Dermatol. 2002 Mar;46(3):414-8 [11862178.001]
  • (PMID = 19967329.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


47. Clark HA, Snedeker SM: Critical evaluation of the cancer risk of dibromochloropropane (DBCP). J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2005;23(2):215-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Results from long-term cancer bioassays in rodents show a statistically significant increase in the incidence of malignant and benign mammary gland tumors in female rats treated orally with DBCP compared to controls and some evidence of increased incidence of mammary fibroadenomas in DBCP low-dose treated female rats exposed by inhalation.
  • Male and female mice exposed to DBCP by inhalation experienced increased tumor incidence in the lungs and nasal cavity compared to controls.
  • Significant increases in tumors of the lung and forestomach have also been reported in female mice treated by a dermal route.
  • Given the persistent nature of DBCP contamination in areas of past use, efforts should be made to continue remediation efforts and follow previously exposed populations for development of certain human cancers, including breast, ovarian, stomach, respiratory, oral and nasal cancers, among others.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROPANE .
  • Hazardous Substances Data Bank. 1,2-DIBROMO-3-CHLOROPROPANE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16291528.001).
  • [ISSN] 1059-0501
  • [Journal-full-title] Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews
  • [ISO-abbreviation] J Environ Sci Health C Environ Carcinog Ecotoxicol Rev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antinematodal Agents; 0 / Carcinogens; 0 / Environmental Pollutants; 96K0FD4803 / 1,2-dibromo-3-chloropropane; T75W9911L6 / Propane
  • [Number-of-references] 118
  •  go-up   go-down


48. Polat A: c-KIT expression in columnar cell lesions of the breast accompanied by benign and malignant breast diseases. Pathol Res Pract; 2007;203(11):765-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] c-KIT expression in columnar cell lesions of the breast accompanied by benign and malignant breast diseases.
  • Columnar cell lesions (CCLs) of the breast are reported with increasing frequency.
  • The aim of the present study was to evaluate c-KIT expression in CCLs accompanying benign and malignant breast diseases.
  • A total of 65 patients (18 benign breast diseases, 8 ductal carcinomas in situ (DCI), and 39 invasive carcinomas) were included in the study. c-KIT was strongly expressed in normal breast epithelium (staining intensity; SI: 3 +/- 0.0), whereas a heterogeneous and cytoplasmic staining pattern was observed in CCLs accompanying both benign and malignant diseases. c-KIT expression was decreased, with increasing atypia in CCLs (SI in CCLs with/without atypia; 1.45 +/- 0.52/no case, 1.25 +/- 0.50/1.38 +/- 0.52, 0.77 +/- 0.73/1.21 +/- 0.42 accompanying benign breast disease, DCI and invasive carcinoma, respectively).
  • No significant association between c-KIT expression and the histologic grade and nodal status of tumor was noted.
  • As there is a reduction in c-KIT expression with malignant transformation of breast epithelium, c-KIT is believed to play a role in breast carcinogenesis.
  • Furthermore, similar c-KIT expression patterns in CCLs accompanying malignant breast diseases suggest that at least some CCLs could reflect a premalignant status of breast carcinoma.
  • However, the significance of c-KIT expression in CCLs and its relationship to breast carcinogenesis should be evaluated in follow up studies investigating larger series.
  • [MeSH-major] Breast Diseases / metabolism. Breast Neoplasms / metabolism. Proto-Oncogene Proteins c-kit / biosynthesis
  • [MeSH-minor] Epithelial Cells / pathology. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17931792.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


49. Elmore L, Margenthaler JA: Breast MRI surveillance in women with prior curative-intent therapy for breast cancer. J Surg Res; 2010 Sep;163(1):58-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast MRI surveillance in women with prior curative-intent therapy for breast cancer.
  • BACKGROUND: We sought to determine factors that predict the use of breast magnetic resonance imaging (MRI) surveillance in women previously treated for breast cancer and the incidence of in-breast recurrences and/or new cancers identified by MRI.
  • METHODS: We reviewed 141 patients who were treated between 2005 and 2008 who also underwent surveillance breast MRI following their treatment.
  • Patient, tumor, treatment characteristics, and MRI findings were collected.
  • Gail scores were calculated based on the patient's personal and family history prior to the breast cancer diagnosis.
  • One hundred forty-one women underwent 202 surveillance breast MRIs during the study period.
  • Two of the six were invasive breast cancers, while four were benign.
  • Patient age, Gail score, tumor stage, grade, histology, receptor status, and surgical treatment were not predictive of MRI surveillance use.
  • CONCLUSION: Prospective studies are needed to determine which patients may potentially benefit from breast MRI surveillance following curative-intent treatment.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Lobular / diagnosis. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20605594.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Sato K, Ueda Y, Shimasaki M, Ozaki M, Nitta N, Chada K, Ishikawa Y, Katsuda S: Pleomorphic adenoma (benign mixed tumor) of the breast: a case report and review of the literature. Pathol Res Pract; 2005;201(4):333-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic adenoma (benign mixed tumor) of the breast: a case report and review of the literature.
  • We report a case of pleomorphic adenoma (benign mixed tumor) of the breast, which is an extremely rare location for this tumor.
  • Examination of a 55-year-old woman unexpectedly revealed a mass measuring 0.8 cm in diameter in the subareolar region of the right breast.
  • Excisional biopsy was performed, and the tumor histologically showed pleomorphic adenoma composed of duct epithelial cells, myoepithelial cells, and a myxochondroid matrix.
  • Sixty-nine cases of this type of tumor arising in the breast have been described previously.
  • Using imaging procedures, the tumor has occasionally been misdiagnosed as malignant clinically and even pathologically in frozen section diagnosis.
  • Careful diagnosis based on paraffin sections is required to avoid unnecessary aggressive surgery, and pathologists should include pleomorphic adenoma in the differential diagnosis of a demarcated, juxtaareolar, small hard mass.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Breast Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. HMGA1a Protein / analysis. HMGA2 Protein / analysis. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Middle Aged. Receptors, Estrogen / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991841.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HMGA2 Protein; 0 / Receptors, Estrogen; 124544-67-8 / HMGA1a Protein
  • [Number-of-references] 32
  •  go-up   go-down


51. Wu HD, Chou SY, Chen DR, Kuo HW: Differentiation of serum levels of trace elements in normal and malignant breast patients. Biol Trace Elem Res; 2006 Oct;113(1):9-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of serum levels of trace elements in normal and malignant breast patients.
  • The objective of this study was to determine which elements in serum best differentiated breast cancer in a case-control study.
  • Concentrations of 13 elements in serum of 68 breast tumor patients (25 malignant and 43 benign) and 26 healthy controls were measured.
  • Sensitivity and specificity of the model were calculated to obtain the optimal cutoff point for discriminating malignant breast cancers vs other individuals (including benign breast disease and normal ones).
  • In conclusion, there was a significant difference in concentrations of all 13 elements in serum between breast cancer patients and controls.
  • A combination among Cd, Mn, Fe, Cr, and Zn might be important to determine a differentiating reference for breast cancers if a long-term followed-up study is to be conducted.
  • [MeSH-major] Breast Neoplasms / blood. Trace Elements / blood
  • [MeSH-minor] Cadmium / blood. Female. Humans. Iron / blood. Logistic Models. Manganese / blood. ROC Curve. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • Hazardous Substances Data Bank. MANGANESE, ELEMENTAL .
  • Hazardous Substances Data Bank. CADMIUM, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17114811.001).
  • [ISSN] 0163-4984
  • [Journal-full-title] Biological trace element research
  • [ISO-abbreviation] Biol Trace Elem Res
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Trace Elements; 00BH33GNGH / Cadmium; 42Z2K6ZL8P / Manganese; E1UOL152H7 / Iron
  •  go-up   go-down


52. Wood ME, Stanley MA, Crocker AM, Kingsley FS, Leiman G: Ductal lavage of cancerous and unaffected breasts: procedure success rate and cancer detection. Acta Cytol; 2009 Jul-Aug;53(4):410-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate ductal lavage (DL) performance in women with known breast cancer and to assess cell yield from contralateral high-risk breasts.
  • STUDY DESIGN: Women with newly diagnosed breast cancer were offered study participation.
  • Samples were interpreted masked as to which breast was malignant, and the interpretation used a 5-category scheme: insufficient, benign, mildly atypical, markedly atypical or malignant.
  • CONCLUSION: The low sensitivity of DL performed on malignant breasts to identify abnormal cells adds to the growing body of evidence that this is not an effective tool in identifying existing breast cancer.
  • [MeSH-major] Breast Neoplasms / pathology. Neoplasms, Multiple Primary / diagnosis. Therapeutic Irrigation / methods
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Breast / pathology. Female. Humans. Middle Aged. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697725.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


53. Ferreira E, Gobbi H, Saraiva BS, Cassali GD: Columnar cell lesions of the canine mammary gland: pathological features and immunophenotypic analysis. BMC Cancer; 2010;10:61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: It has been suggested that columnar cell lesions indicate an alteration of the human mammary gland involved in the development of breast cancer.
  • The aim of this paper is describe the morphologic spectrum of columnar cell lesions in canine mammary gland specimens and their association with other breast lesions.
  • METHODS: A total of 126 lesions were subjected to a comprehensive morphological review based upon the human breast classification system for columnar cell lesions.
  • Sixty (89.5%) of the columnar cell lesions coexisted with neoplastic lesions (20 in situ carcinomas, 19 invasive carcinomas and 21 benign tumors).
  • CONCLUSIONS: Columnar cell lesions in canine mammary gland are pathologically and immunophenotypically similar to those in human breast.
  • This may suggest that dogs are a suitable model for the comparative study of noninvasive breast lesions.
  • [MeSH-minor] Animals. Biopsy. Cadherins / biosynthesis. Disease Models, Animal. Dogs. Female. Immunophenotyping. Keratins / metabolism. Ki-67 Antigen / biosynthesis. Receptor, ErbB-2 / biosynthesis. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Tumor Suppressor Protein p53 / biosynthesis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1976 Jul;57(1):57-61 [1034018.001]
  • [Cites] Am J Pathol. 1974 Apr;75(1):225-8 [4825616.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):105-8 [15613861.001]
  • [Cites] Breast J. 2005 Mar-Apr;11(2):140-2 [15730461.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):734-46 [15897740.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):803-19 [16341006.001]
  • [Cites] Mod Pathol. 2006 Mar;19(3):344-9 [16400324.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):417-26 [17325484.001]
  • [Cites] Histopathology. 2007 Jun;50(7):859-65 [17543075.001]
  • [Cites] Cytopathology. 2007 Jun;18(3):191-6 [17573766.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2247-56 [17982119.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1307-12 [17182657.001]
  • [Cites] BMC Cancer. 2007;7:218 [18045453.001]
  • [Cites] Virchows Arch. 2008 Jun;452(6):589-98 [18437416.001]
  • [Cites] Mod Pathol. 2008 Dec;21(12):1413-20 [18820672.001]
  • [Cites] Arch Pathol Lab Med. 2007;131(1):18-43 [19548375.001]
  • [Cites] Am J Surg Pathol. 1999 Dec;23(12):1561 [10584711.001]
  • [Cites] Cancer Invest. 2000;18(8):781-92 [11107448.001]
  • [Cites] Breast Cancer Res. 2002;4(2):47-50 [11879561.001]
  • [Cites] Adv Anat Pathol. 2003 May;10(3):113-24 [12717115.001]
  • [Cites] Breast Cancer Res. 2003;5(5):263-8 [12927037.001]
  • [Cites] Breast Cancer Res Treat. 2003 Aug;80(3):363-7 [14503809.001]
  • [Cites] Breast Cancer Res. 2003;5(6):313-9 [14580249.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1521-7 [9850178.001]
  • (PMID = 20178635.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins; 0 / Ki-67 Antigen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 68238-35-7 / Keratins; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2841138
  •  go-up   go-down


54. Celis JE, Gromov P, Moreira JM, Cabezón T, Friis E, Vejborg IM, Proess G, Rank F, Gromova I: Apocrine cysts of the breast: biomarkers, origin, enlargement, and relation with cancer phenotype. Mol Cell Proteomics; 2006 Mar;5(3):462-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine cysts of the breast: biomarkers, origin, enlargement, and relation with cancer phenotype.
  • Up to one-third of women aged 30-50 years have cysts in their breasts and are presumed to be at increased risk of developing breast cancer.
  • Here we present an extensive proteomic and immunohistochemistry (IHC) study of breast apocrine cystic lesions aimed at generating specific biomarkers and elucidating the relationship, if existent, of apocrine cysts with cancer phenotype.
  • The successful identification of differentially expressed proteins that characterize specific steps in the progression from early benign lesions to apocrine cancer opens a window of opportunity for designing and testing new approaches for pharmacological intervention, not only in a therapeutic setting but also for chemoprevention, to inhibit cyst development as both 15-hydroxyprostaglandin dehydrogenase and 3-hydroxymethylglutaryl-CoA reductase are currently being targeted for chemoprevention strategies in various malignancies.
  • [MeSH-major] Apocrine Glands / pathology. Biomarkers, Tumor / analysis. Breast / pathology. Breast Neoplasms / pathology. Cysts / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cyst Fluid / chemistry. Cytokines / metabolism. Female. Humans. Hydroxymethylglutaryl CoA Reductases / metabolism. Hydroxyprostaglandin Dehydrogenases / metabolism. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Proteins / chemistry. Neoplasm Staging. Patient Selection. Phenotype. Proteome / analysis. Proteome / chemistry. Reproducibility of Results

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16316978.001).
  • [ISSN] 1535-9476
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytokines; 0 / Neoplasm Proteins; 0 / Proteome; EC 1.1.1.- / Hydroxymethylglutaryl CoA Reductases; EC 1.1.1.- / Hydroxyprostaglandin Dehydrogenases; EC 1.1.1.141 / 15-hydroxyprostaglandin dehydrogenase
  •  go-up   go-down


55. Shin SJ, Lesser M, Rosen PP: Hemangiomas and angiosarcomas of the breast: diagnostic utility of cell cycle markers with emphasis on Ki-67. Arch Pathol Lab Med; 2007 Apr;131(4):538-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemangiomas and angiosarcomas of the breast: diagnostic utility of cell cycle markers with emphasis on Ki-67.
  • CONTEXT: Vascular tumors comprise a minor subgroup of tumors arising in the breast and represent variants of hemangiomas and angiosarcomas.
  • Ki-67 expression has been used as an adjunct to distinguish between benign and malignant lesions exhibiting histologic overlap at various anatomic sites.
  • OBJECTIVE: To investigate the utility of Ki-67 and other cell cycle regulatory proteins (S-phase kinase-associated protein 2 [Skp2], p27, and cyclin D1) in the differential diagnosis of mammary vascular lesions.
  • DESIGN: Thirty-four vascular tumors (21 hemangiomas and 13 angiosarcomas) of the breast were studied.
  • CONCLUSIONS: Ki-67 index can be used as a diagnostic tool to distinguish between benign and malignant vascular lesions of the breast.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms, Male / diagnosis. Hemangioma / diagnosis. Hemangiosarcoma / diagnosis. Ki-67 Antigen / metabolism
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cell Cycle. Cyclin D1 / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Proliferating Cell Nuclear Antigen / metabolism. S-Phase Kinase-Associated Proteins / metabolism. Sensitivity and Specificity


56. Perkins RS, Sahm K, Marando C, Dickson-Witmer D, Pahnke GR, Mitchell M, Petrelli NJ, Berkowitz IM, Soteropoulos P, Aris VM, Dunn SP, Krueger LJ: Analysis of Epstein-Barr virus reservoirs in paired blood and breast cancer primary biopsy specimens by real time PCR. Breast Cancer Res; 2006;8(6):R70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of Epstein-Barr virus reservoirs in paired blood and breast cancer primary biopsy specimens by real time PCR.
  • This infection is considered benign, even though in limited cases EBV is associated with infectious and neoplastic conditions.
  • Over the past decade, the EBV association with breast cancer has been constantly debated.
  • Adding to this clinical and biological uncertainty, different techniques gave contradictory results for the presence of EBV in breast carcinoma specimens.
  • In this study, minor groove binding (MGB)-TaqMan real time PCR was used to detect the presence of EBV DNA in both peripheral blood and tumor samples of selected patients.
  • METHODS: Peripheral blood and breast carcinoma specimens from 24 patients were collected.
  • RESULTS: Of 24 breast tumor specimens, 11 (46%) were positive for EBV DNA.
  • Of these 11 breast tumor specimens, 7 (64%) were also positive for EBV DNA in the peripheral blood, while 4 (36%) were positive for EBV DNA in the tumor, but negative in the blood.
  • Furthermore, our finding of the presence of EBV in the tumor specimens coupled to the absence of detection of EBV genomic DNA in the peripheral blood is consistent with the epithelial nature of the virus.
  • Because of the low levels of viral DNA in tumor tissue, further studies are needed to assess the biological input of EBV in breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Jan;156(1):1-3 [10623645.001]
  • [Cites] J Virol. 1999 Oct;73(10):8857-66 [10482644.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1849-51 [11078764.001]
  • [Cites] J Natl Cancer Inst. 2001 Jan 17;93(2):148-50 [11208885.001]
  • [Cites] Br J Cancer. 2001 Mar 23;84(6):783-90 [11259092.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):571-8 [11485915.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Virology. 2001 Sep 30;288(2):223-35 [11601894.001]
  • [Cites] Nat Med. 2002 Jun;8(6):594-9 [12042810.001]
  • [Cites] Mod Pathol. 2002 Jul;15(7):759-64 [12118114.001]
  • [Cites] Lab Invest. 2002 Sep;82(9):1193-9 [12218080.001]
  • [Cites] Breast Cancer Res. 2003;5(1):R13-7 [12559053.001]
  • [Cites] Nat Med. 2003 Mar;9(3):307-14 [12592401.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2338-43 [12727860.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):113-9 [12838311.001]
  • [Cites] J Natl Cancer Inst. 2003 Aug 20;95(16):1253-4; author reply 1254-5 [12928356.001]
  • [Cites] J Virol. 2003 Dec;77(24):13267-74 [14645583.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):832-44 [14668814.001]
  • [Cites] Mod Pathol. 2003 Dec;16(12):1242-7 [14681325.001]
  • [Cites] Eur J Haematol. 2004 Mar;72(3):203-12 [14962239.001]
  • [Cites] Med Hypotheses. 2004;62(3):387-91 [14975509.001]
  • [Cites] J Virol. 2004 May;78(10):5007-14 [15113881.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):688-97 [15159298.001]
  • [Cites] J Gen Virol. 2004 Oct;85(Pt 10):2767-78 [15448337.001]
  • [Cites] J Mol Diagn. 2004 Nov;6(4):378-85 [15507678.001]
  • [Cites] Cell. 1988 Jan 15;52(1):51-61 [2830981.001]
  • [Cites] J Clin Pathol. 1994 Jun;47(6):538-40 [8063937.001]
  • [Cites] Cancer Res. 1995 Jan 1;55(1):39-45 [7805038.001]
  • [Cites] Am J Clin Pathol. 1995 Mar;103(3):308-15 [7872253.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1996;67:1-424 [9190379.001]
  • [Cites] Int J Cancer. 1998 Feb 9;75(4):555-8 [9466655.001]
  • [Cites] Cancer Lett. 1998 Feb 13;124(1):53-7 [9500191.001]
  • [Cites] Diagn Mol Pathol. 2005 Mar;14(1):29-33 [15714061.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):809-14 [15824148.001]
  • [Cites] Breast Cancer Res. 2005;7(3):86-95 [15987436.001]
  • [Cites] J Virol. 2006 Jan;80(2):845-53 [16378986.001]
  • [Cites] J Virol. 1998 May;72(5):4371-8 [9557727.001]
  • [Cites] Cancer Res. 1998 Jul 1;58(13):2825-31 [9661897.001]
  • [Cites] Ann Med. 1998 Jun;30(3):249-59 [9677010.001]
  • [Cites] J Virol. 1999 Feb;73(2):1286-92 [9882333.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 18;91(16):1349-50 [10451431.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 18;91(16):1376-81 [10451442.001]
  • [Cites] J Natl Cancer Inst. 2000 Apr 19;92(8):655-6; author reply 656 [10772685.001]
  • (PMID = 17163997.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR016472; United States / NCRR NIH HHS / RR / 2 P20 RR016472-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC1797024
  •  go-up   go-down


57. Sanati S, Leonard M, Khamapirad T, Eltorky MA: Nodular mucinosis of the breast: a case report with pathologic, ultrasonographic, and clinical findings and review of the literature. Arch Pathol Lab Med; 2005 Mar;129(3):e58-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular mucinosis of the breast: a case report with pathologic, ultrasonographic, and clinical findings and review of the literature.
  • Nodular mucinosis is an extremely rare breast lesion.
  • This benign mass usually presents clinically as a poorly circumscribed, subareolar, myxoid mass in young female patients.
  • We report a case of this rare breast lesion and discuss its clinical, radiologic, and histopathologic features.
  • A 21-year-old white woman presented with a mass in the left breast of 6 months' duration.
  • She had never been pregnant or had any history of breast feeding, surgery, trauma, or use of exogenous hormones or a family history of breast cancer.
  • Clinical breast examination demonstrated a 1 cm "rubbery" mass directly under and continuous with the left nipple.
  • These findings suggested a benign breast lesion, including a fibroadenoma or nipple adenoma.
  • Microscopic examination showed a well-circumscribed tumor with a nodular appearance, which consisted of an accumulation of pink myxoid tissue and contained spindle cells with bland-appearing nuclei, no mitosis, and mild cellularity.
  • [MeSH-major] Breast / pathology. Mucinoses / diagnosis. Skin Diseases / diagnosis
  • [MeSH-minor] Adult. Female. Humans

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737051.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


58. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast RC Jr, Lokshin AE: Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol; 2010 May 01;28(13):2159-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Ninety-six serum biomarkers were analyzed in sera from healthy women and from patients with ovarian cancer, benign pelvic tumors, and breast, colorectal, and lung cancers, using multiplex xMAP bead-based immunoassays.
  • This panel was selective for ovarian cancer showing SN of 33% for benign pelvic disease, SN of 6% for breast cancer, SN of 0% for colorectal cancer, and SN of 36% for lung cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Immunoassay. Mass Screening / methods. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Algorithms. CA-125 Antigen / blood. Carcinoembryonic Antigen / blood. Data Interpretation, Statistical. Early Detection of Cancer. Epididymal Secretory Proteins / analysis. Female. Humans. Middle Aged. Monte Carlo Method. Neoplasm Staging. Predictive Value of Tests. Prognosis. Reproducibility of Results. Sensitivity and Specificity. Vascular Cell Adhesion Molecule-1 / blood. beta-Defensins

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2010 May 1;28(13):2128-30 [20368556.001]
  • [Cites] Cancer Chemother Biol Response Modif. 1999;18:418-34 [10800496.001]
  • [Cites] Life Sci. 2001 Jan 12;68(8):861-72 [11213356.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):656-63 [16112717.001]
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):643-50 [11237385.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):194s-199s [12743134.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):355-66 [14764655.001]
  • [Cites] Mol Pathol. 2002 Apr;55(2):110-20 [11950960.001]
  • [Cites] J Cancer Res Clin Oncol. 1989;115(5):456-8 [2808485.001]
  • [Cites] Gynecol Obstet Invest. 1999;48(2):133-7 [10461006.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):129-37 [10067810.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):47-54 [19007974.001]
  • [Cites] Gynecol Oncol. 1988 Jun;30(2):265-73 [3163666.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1035-43 [12637468.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2837-44 [11753957.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6D):4735-7 [9494598.001]
  • [Cites] Clin Biochem. 2003 Mar;36(2):135-43 [12633763.001]
  • [Cites] Dis Markers. 2007;23(5-6):419-31 [18057525.001]
  • [Cites] JAMA. 1995 Dec 27;274(24):1926-30 [8568986.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2190-6 [10786683.001]
  • [Cites] Tumour Biol. 1993;14(2):105-15 [8392219.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 2005 Jun;45(3):211-4 [15904446.001]
  • [Cites] Curr Oncol Rep. 2002 Mar;4(2):165-74 [11822989.001]
  • [Cites] J Endocrinol Invest. 2004 Jun;27(6):528-34 [15717649.001]
  • [Cites] Curr Opin Obstet Gynecol. 2001 Feb;13(1):61-4 [11176234.001]
  • [Cites] Cancer. 1975 May;35(5):1377-81 [47262.001]
  • [Cites] Int J Cancer. 2003 Sep 10;106(4):605-10 [12845660.001]
  • [Cites] Clin Exp Metastasis. 1999 Mar;17(2):131-40 [10411105.001]
  • [Cites] Hum Reprod. 1989 Jan;4(1):1-12 [2651469.001]
  • [Cites] Br J Obstet Gynaecol. 1993 Dec;100(12):1120-4 [8297846.001]
  • [Cites] Gene. 1999 Oct 1;238(2):375-85 [10570965.001]
  • [Cites] Gynecol Oncol. 2007 Oct;107(1):58-65 [17659325.001]
  • [Cites] J Surg Oncol. 1990 Jun;44(2):97-9 [2355747.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):464-75 [16083703.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7 [15824174.001]
  • [Cites] Semin Surg Oncol. 2000 Jul-Aug;19(1):3-10 [10883018.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1880-3 [18708375.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2380-6 [11489816.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):122-4 [7686390.001]
  • [Cites] Acta Obstet Gynecol Scand. 1997 Mar;76(3):283-5 [9093148.001]
  • [Cites] Cancer Lett. 2007 Apr 28;249(1):61-79 [17275179.001]
  • [Cites] Semin Surg Oncol. 1994 Jul-Aug;10(4):242-8 [8091065.001]
  • [Cites] Ann Acad Med Singapore. 1998 Sep;27(5):676-82 [9919339.001]
  • [Cites] Br J Obstet Gynaecol. 1992 Apr;99(4):329-32 [1581280.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1065-72 [18258665.001]
  • [Cites] Br J Cancer. 1994 Dec;70(6):1186-7 [7981074.001]
  • [Cites] Crit Rev Clin Lab Sci. 2004;41(3):265-312 [15307634.001]
  • [Cites] Clin Sci (Lond). 2006 Mar;110(3):279-91 [16464170.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7677-82 [15890779.001]
  • [Cites] Int J Gynecol Cancer. 2001 Jul-Aug;11(4):277-82 [11520365.001]
  • [Cites] Cancer Treat Res. 2002;107:247-58 [11775453.001]
  • [Cites] Gynecol Oncol. 1988 Jan;29(1):66-75 [3422208.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3030-5 [10487660.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2771-4 [12782581.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4059-66 [15381683.001]
  • [Cites] Medscape Womens Health. 1996 Nov;1(11):3 [9746655.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4721-8 [17214332.001]
  • [Cites] Eur J Cancer Prev. 1998 Feb;7(1):23-35 [9511849.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):9-15 [15385104.001]
  • [Cites] Lancet. 1999 Apr 10;353(9160):1207-10 [10217079.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):103-13 [12582019.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7919-26 [16258091.001]
  • [Cites] Gynecol Oncol. 1997 Jul;66(1):27-30 [9234916.001]
  • [Cites] Cytokine. 2009 Jan;45(1):44-9 [19058974.001]
  • [Cites] Biomed Biochim Acta. 1986;45(3):371-84 [3518711.001]
  • [Cites] Med Oncol. 2008;25(3):279-83 [18071928.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Anticancer Res. 1994 Nov-Dec;14(6B):2743-6 [7532929.001]
  • [Cites] Br J Obstet Gynaecol. 1997 Sep;104(9):1024-9 [9307529.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4B):2891-4 [9713482.001]
  • [Cites] Eur J Gynaecol Oncol. 2000;21(2):135-40 [10843471.001]
  • [Cites] Fertil Steril. 2003 Oct;80(4):1068-9; author reply 1069-70 [14556841.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3695-700 [12839961.001]
  • [Cites] Br J Obstet Gynaecol. 1979 Nov;86(11):901-4 [116672.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 3;85(21):1748-51 [8411259.001]
  • [Cites] Hum Reprod. 2005 Jan;20(1):117-21 [15513972.001]
  • [Cites] Tumour Biol. 2002 May-Jun;23(3):185-92 [12218299.001]
  • [Cites] Cancer Invest. 1995;13(2):227-38 [7874576.001]
  • [Cites] Immunol Invest. 2006;35(2):167-79 [16698675.001]
  • [Cites] Eur Cytokine Netw. 2009 Mar;20(1):21-6 [19318317.001]
  • [Cites] Gynecol Oncol. 1998 Jun;69(3):248-52 [9648596.001]
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1B):569-72 [10769727.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81 [16343244.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5882-90 [15313933.001]
  • [Cites] Int J Oncol. 2005 Feb;26(2):379-84 [15645122.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2005 May 1;120(1):87-90 [15866092.001]
  • [Cites] Biomed Pharmacother. 2004 Jan;58(1):24-38 [14739059.001]
  • [Cites] Cancer. 2007 Jul 15;110(2):297-308 [17569106.001]
  • [Cites] Eur J Clin Chem Clin Biochem. 1994 Mar;32(3):201-7 [8031969.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1641-6 [16985025.001]
  • [Cites] Am Fam Physician. 2003 Sep 15;68(6):1075-82 [14524394.001]
  • (PMID = 20368574.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098642; United States / NCI NIH HHS / CA / CA105009; United Kingdom / Medical Research Council / / G9901012; United States / NCI NIH HHS / CA / R01 CA108990; United Kingdom / Medical Research Council / / G0801228; United States / NCI NIH HHS / CA / U01 CA086381; United States / NCI NIH HHS / CA / P50 CA105009; United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / CA086381
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / Vascular Cell Adhesion Molecule-1; 0 / beta-Defensins
  • [Other-IDs] NLM/ PMC2860434
  •  go-up   go-down


59. Liu HM, Wu FL, Chen X, Ye CS, Deng YJ: [Value of ultrasonographic grading with high-frequency probes in distinguishing breast tumors]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Oct;29(10):2115-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Value of ultrasonographic grading with high-frequency probes in distinguishing breast tumors].
  • OBJECTIVE: To investigate the value of ultrasonographic grading with high-frequency probes in differentiating benign and malignant breast tumors.
  • METHODS: Sixty-four women (mean age 44.5-/+13.7 years) with 79 breast tumors underwent high-frequency ultrasonography to examine the tumor number, size, aspect ratio, shape, boundaries, encapsulation, pseudopod, internal and rear echoes, calcifications, blood perfusion, abnormality lymph nodes in the axilla.
  • RESULTS: Between the 46 women with benign tumors and 18 with malignant tumors, no significant differences were found in the mean tumor number (1.5-/+1.3 vs 1.1-/+0.3, P>0.05) or size (55.0-/+19.2 mm vs 19.8-/+8.3 mm, P>0.05), but the mean age (41.4-/+12.4 years vs 52.4-/+14.1 years) and ultrasonographic grade (2.8-/+2.2 vs 7.3-/+1.7, P<0.05) differed significantly.
  • The ultrasonographic grade of the breast tumors showed an obvious correlation to the nature of the tumors (r=0.695, P<0.001).
  • CONCLUSION: Grading of breast tumors with high-frequency ultrasonography helps evaluate the nature of the tumors, and a higher score suggests increased probability of malignancy.
  • [MeSH-major] Breast Diseases / ultrasonography. Breast Neoplasms / ultrasonography. Ultrasonography, Mammary / methods
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Grading. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19861280.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


60. Piana S, Asioli S, Cavazza A: Benign Müllerian inclusions coexisting with breast metastatic carcinoma in an axillary lymph node. Virchows Arch; 2005 Apr;446(4):467-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign Müllerian inclusions coexisting with breast metastatic carcinoma in an axillary lymph node.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Lymph Nodes / pathology. Mullerian Ducts / pathology
  • [MeSH-minor] Adult. Axilla. Biomarkers, Tumor / analysis. Female. Humans. Inclusion Bodies / chemistry. Inclusion Bodies / pathology. Keratins / analysis. Lymphatic Metastasis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1999 Oct;23(10):1264-9 [10524528.001]
  • [Cites] Surg Today. 1999;29(3):264-5 [10192739.001]
  • [Cites] Hum Pathol. 2003 Feb;34(2):194-8 [12612890.001]
  • [Cites] Int J Surg Pathol. 2001 Apr;9(2):155-62 [11484504.001]
  • [Cites] Am J Surg Pathol. 1983 Apr;7(3):293-300 [6837837.001]
  • [Cites] Pathol Res Pract. 1995 Oct;191(10):991-6 [8838366.001]
  • [Cites] Arch Pathol Lab Med. 1995 Sep;119(9):841-4 [7668944.001]
  • (PMID = 15785927.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 68238-35-7 / Keratins
  •  go-up   go-down


61. Nassar A, Amin MB, Sexton DG, Cohen C: Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer. Appl Immunohistochem Mol Morphol; 2005 Sep;13(3):252-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, AMACR has been demonstrated to be overexpressed in localized and metastatic prostate cancer and in high-grade prostatic intraepithelial neoplasia but not in normal prostatic glands, suggesting that it may be an important tumor marker.
  • This study examines AMACR expression in a variety of human cancers to assess its viability as a tumor marker in the clinical setting.
  • Cancers studied included breast (94 cases), prostate (38), lung (28), endometrium (27), colon (29), ovary (26), and melanoma (21).
  • A section of prostate cancer and prostatic intraepithelial neoplasia was used as positive control.
  • AMACR protein overexpression was found in several cancers, including prostate (34/38 [89.5%]), colon (13/29 [44.8%]), lung (4/28 [14.3%]), melanoma (2/21 [9.5%]), endometrium (2/27 [7.4%]), and breast (3/94 [3.2%]).
  • AMACR expression was not present in any of the normal tissues nor in benign prostatic tissue associated with prostate carcinomas.
  • This study suggests that AMACR is potentially an important tumor marker, particularly for prostate and colon cancer.
  • It may be a useful adjunct to an immunohistochemical panel employed in the differential diagnosis of colon versus ovarian and breast carcinoma; the latter two infrequently express AMACR.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16082251.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


62. Bereznaya NM, Kirnasovskaya EA, Vinnichuk YD, Belova OB, Lukyanova NY: Expression of CD40 by the cells of benign and malignant breast tumors and antitumor action of autologous lymphocytes against chemoresistant and chemosensitive tumors. Exp Oncol; 2008 Dec;30(4):295-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CD40 by the cells of benign and malignant breast tumors and antitumor action of autologous lymphocytes against chemoresistant and chemosensitive tumors.
  • AIM: To study the expression of CD40 by cells of benign and malignant tumors of mammary gland, and to compare the efficacy of lymphocytes antitumor activity against drug resistant and sensitive breast tumors in relevance to CD40 expression.
  • METHODS: Breast tumor explants were cultured with autologous lymphocytes in double diffusion chambers.
  • Expression level of molecules on tumor cells was analyzed using immunohistochemical method (paraffin embedded slides), and on lymphocytes - by the method of indirect immunofluorescence.
  • RESULTS: The highest level of CD40 expression was detected on cells of chemoresistant malignant breast tumors, and the lowest one - on cells of benign breast tumors.
  • The decreased CD40 expression on lymphocytes from patients with drug resistant breast cancer was compared with that on lymphocytes of the patients with drug sensitive breast cancer.
  • The study of antitumor activity of autologous lymphokine activated killer cells (LAK) has shown their pronounced antitumor activity against drug resistant malignant breast tumors.
  • CONCLUSION: Marked antitumor activity of LAK from the patients with drug resistant breast cancer is associated with high expression level of CD40 on tumor cells and with its decreased expression on lymphocytes.
  • [MeSH-major] Antigens, CD40 / biosynthesis. Breast Neoplasms / immunology. Drug Resistance, Neoplasm / immunology. Killer Cells, Lymphokine-Activated / immunology
  • [MeSH-minor] Female. Fluorescent Antibody Technique. Humans. Immunohistochemistry. Intercellular Adhesion Molecule-1 / immunology. Intercellular Adhesion Molecule-1 / metabolism. Lymphocytes / immunology. Lymphocytes / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112427.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antigens, CD40; 126547-89-5 / Intercellular Adhesion Molecule-1
  •  go-up   go-down


63. Korula A, Varghese J, Thomas M, Vyas F, Korula A: Malignant phyllodes tumour with intraductal and invasive carcinoma and lymph node metastasis. Singapore Med J; 2008 Nov;49(11):e318-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phyllodes tumours constitute 2-3 percent of fibroepithelial breast tumours, with a 1-2 percent rate of malignancy.
  • Carcinoma in a phyllodes tumour is distinctly uncommon, but has been known to occur in benign phyllodes tumours.
  • We describe a 51-year-old woman with a malignant phyllodes tumour with foci of intraductal carcinoma within the tumour and adjacent breast tissue.
  • Though the carcinoma was found to be invasive based on the presence of carcinomatous lymph node metastasis, extensive sampling did not yield an invasive component within the breast, probably because of the marked stromal overgrowth of the phyllodes.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Carcinoma / diagnosis. Carcinoma / pathology. Phyllodes Tumor / diagnosis. Phyllodes Tumor / pathology
  • [MeSH-minor] Breast / pathology. Breast / surgery. Female. Humans. Immunohistochemistry. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19037540.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


64. Oo KZ, Xiao PQ: Infiltrating syringomatous adenoma of the nipple: clinical presentation and literature review. Arch Pathol Lab Med; 2009 Sep;133(9):1487-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infiltrating syringomatous adenoma of the nipple is a rare neoplasm of the breast.
  • Despite its benign behavior, syringomatous adenoma of the nipple usually shows infiltrative expansile proliferation into adjacent tissue and underlying breast tissue.
  • Histologically and clinically, syringomatous adenoma of the nipple is often confused with tubular carcinoma as well as low-grade adenosquamous carcinoma of the breast.
  • Special attention given to this tumor by pathologists and clinicians can avoid misdiagnosis and unnecessary treatment.
  • [MeSH-major] Breast Neoplasms / pathology. Nipples / pathology. Sweat Gland Neoplasms / pathology. Syringoma / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adolescent. Adult. Aged. Child. Diagnosis, Differential. Female. Humans. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19722761.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


65. Tamura T, Usui S, Murakami S, Arihiro K, Akiyama Y, Naito K, Akiyama M: Biexponential Signal Attenuation Analysis of Diffusion-weighted Imaging of Breast. Magn Reson Med Sci; 2010;9(4):195-207
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biexponential Signal Attenuation Analysis of Diffusion-weighted Imaging of Breast.
  • In this study, we investigated the clinical utility of DWI for the breast by performing DWI using multiple b-factors on healthy volunteers and clinical subjects, analyzing the signal by fitting it with a biexponential equation, and comparing the fitting parameters of breast lesions.
  • PATIENTS AND METHODS: we investigated 8 healthy women as normal cases and 80 female patients with a total of 100 breast tumors (42 benign, 58 malignant tumors) as clinical cases.
  • Comparison of parameters derived from biexponential fitting demonstrated no significant difference between benign and malignant lesions.
  • For malignant tumor subtype, the fast component fraction of noninvasive ductal carcinoma was statistically greater than that of invasive ductal carcinoma.
  • CONCLUSIONS: although the parameters from biexponential fitting may reflect the character of tumor cellularity, because pathological diagnosis was performed with an emphasis on cell configuration or shape rather than cellularity, it was difficult to distinguish malignant from benign tumors, including many IDPs, or to distinguish tissue types using DWI signal attenuation alone.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Diffusion Magnetic Resonance Imaging / methods. Fibroadenoma / pathology. Papilloma, Intraductal / pathology. Signal Processing, Computer-Assisted
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Breast / pathology. Breast Diseases / pathology. Diagnosis, Differential. Female. Humans. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187689.001).
  • [ISSN] 1880-2206
  • [Journal-full-title] Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine
  • [ISO-abbreviation] Magn Reson Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


66. Zerkowski MP, Camp RL, Burtness BA, Rimm DL, Chung GG: Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome. Cancer Invest; 2007 Feb;25(1):19-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome.
  • Epidemiologic and preclinical studies suggest that cyclooxygenase-2 (Cox-2) may promote tumor growth and spread by affecting angiogenesis and apoptosis in breast cancer.
  • Our TMA consisted of 669 Stage I-III primary breast cancers.
  • The total tumor and subcellular expression of Cox-2 were then correlated with clinicopathologic factors and with survival.
  • Cox-2 expression appeared higher in malignant than in benign tissue and was predominantly membrane/cytoplasmic (i.e. non-nuclear).
  • Multivariate analysis showed that Cox-2 remained a significant prognostic factor for survival independent of tumor size, nodal status, ER, Her2/neu, and grade.
  • In summary, Cox-2 is overexpressed in breast neoplasms, is associated with other markers of poor prognosis, and is significantly associated with worse survival independent of known prognostic factors.
  • Furthermore, AQUA and X-tile analysis suggest an optimal cutpoint that may be helpful in future investigations of Cox-2 and specifically, in studies looking at its expression as a predictive biomarker in clinical trials of Cox-2 inhibitors in breast cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cyclooxygenase 2 / biosynthesis. Membrane Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Image Processing, Computer-Assisted. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Prognosis. Tissue Array Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17364553.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


67. Oh JG, Yoon CH, Lee CW: Case of Cowden syndrome associated with eccrine angiomatous hamartoma. J Dermatol; 2007 Feb;34(2):135-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cowden syndrome, also known as multiple hamartoma syndrome is a rare autosomal dominant disorder characterized by multiple hamartomatous tumors of ectodermal, mesodermal and endodermal origin.
  • She had total abdominal hysterectomy due to uterine leiomyoma at the age of 35, and had modified radical mastectomy due to right breast cancer at 38.
  • Histological examination of the skin lesion on the left foot showed an increased numbers of eccrine sweat glands and blood vessels, which are characteristic histological findings of eccrine angiomatous hamartoma (EAH), a rare benign tumor.
  • [MeSH-minor] Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Cowden Syndrome.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17239153.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


68. Balasenthil S, Broaddus RR, Kumar R: Expression of metastasis-associated protein 1 (MTA1) in benign endometrium and endometrial adenocarcinomas. Hum Pathol; 2006 Jun;37(6):656-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of metastasis-associated protein 1 (MTA1) in benign endometrium and endometrial adenocarcinomas.
  • Endometrial carcinoma is one of the most common malignancies of the female genital tract.
  • Metastasis-associated protein 1 (MTA1) is a component of the Mi-2/nucleosome remodeling and deacetylating complex and acts as a potent corepressor of estrogen receptor in breast cancer cells.
  • We investigated the expression profile of MTA1 in different stages of benign endometrium as well as in endometrial endometrioid adenocarcinoma using immunohistochemistry and Western blotting.
  • Western blot analysis of 6 tumor specimens showed increased expression of MTA1 in all the tumors analyzed.
  • Immunohistochemical staining performed on tumor microarray containing 70 endometrial endometrioid adenocarcinomas of various grades showed increased expression of MTA1 in 53 (75.7%) tumors.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cell Nucleus / metabolism. Cytoplasm / metabolism. Female. Humans. Immunohistochemistry. Neoplasm Staging

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16733204.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 098823
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Repressor Proteins; EC 3.5.1.- / Mta1 protein, human; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


69. Aghaei M, Karami-Tehrani F, Salami S, Atri M: Diagnostic value of adenosine deaminase activity in benign and malignant breast tumors. Arch Med Res; 2010 Jan;41(1):14-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of adenosine deaminase activity in benign and malignant breast tumors.
  • BACKGROUND AND AIMS: The present study was carried out to evaluate the activity of adenosine deaminase (ADA) and its isoenzymes ADA1 and ADA2 activities as a diagnostic tool in patients with benign and malignant breast disease.
  • METHODS: Total ADA, ADA1, and ADA2 activities of serum and tumor were analyzed using 58 subjects including 20 patients with benign breast disease (BBD), 34 patients with primary breast cancer, and 20 patients as normal control subjects.
  • RESULTS: The mean values for total ADA and ADA2 activities in the serum and tumor of BBD were significantly higher than those of healthy controls (p <0.01).
  • Furthermore, the mean values for total ADA and ADA2 activities of patients with breast cancer were significantly higher than those of the benign group (p <0.005) and healthy subjects (p <0.0001).
  • CONCLUSIONS: Based on the present results, it is concluded that the assessment of total ADA and ADA2 activities may be used as a reliable test for differential diagnosis of benign and malignant breast disease.
  • [MeSH-major] Adenosine Deaminase / metabolism. Breast Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 IMSS. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20430249.001).
  • [ISSN] 1873-5487
  • [Journal-full-title] Archives of medical research
  • [ISO-abbreviation] Arch. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.5.4.4 / Adenosine Deaminase
  •  go-up   go-down


70. El-Attar NI, Gaefar HA: Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor. Egypt J Immunol; 2007;14(2):111-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
  • Breast cancer (BC) is the most frequent malignant tumor in women worldwide; its recurrence is a result of undetected metastasis present at the time of primary patient treatment.
  • The detection of cell-free RNA in plasma and serum of human subjects has found increasing applications in the field of medical diagnostics.This study aimed at evaluating plasma mammaglobin mRNA as a useful tumor marker for the diagnosis and the detection of metastasis in breast cancer at the time of diagnosis either alone or in combination with conventional serum tumor markers CA15.3 and/or CEA.
  • This study included 40 Egyptian females with primary breast cancer and 25 with different benign breast diseases.
  • There was a significance increase in plasma mammaglobin mRNA expression, CA15.3 and CEA levels in BC group as compared to benign group (p < 0.001).
  • No significant difference was observed between levels of plasma mammaglobin mRNA expression in patients with tumor's size or grade.
  • No correlation was observed with plasma mammaglobulin mRNA levels and tumor size or grading, CEA and CA15.3.
  • There was a significant difference (p < 0.05) and a positive correlation between CA 15.3 and CEA levels in patients with tumor size and grading.
  • In conclusion, plasma mammaglobin mRNA alone or in combination with CA15.3 may be used as a valuable noninvasive approach for the diagnosis and the detection of metastasis in breast cancer at the time of diagnosis.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306663.001).
  • [ISSN] 1110-4902
  • [Journal-full-title] The Egyptian journal of immunology
  • [ISO-abbreviation] Egypt J Immunol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Mammaglobin A; 0 / Mucin-1; 0 / Myelin Proteins; 0 / Neoplasm Proteins; 0 / Proteolipids; 0 / RNA, Messenger; 0 / SCGB2A2 protein, human; 0 / Secretoglobins; 9060-09-7 / Uteroglobin
  •  go-up   go-down


71. Wu ZS, Wu Q, Ding XD, Wang HQ, Shen YX, Fang SY: [Expression of a novel metastasis-inducing protein human anterior gradient-2 (AGR2) in breast cancer and its clinical and prognostic significance]. Zhonghua Bing Li Xue Za Zhi; 2008 Feb;37(2):109-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of a novel metastasis-inducing protein human anterior gradient-2 (AGR2) in breast cancer and its clinical and prognostic significance].
  • OBJECTIVE: To investigate the expression of a novel metastasis-inducing protein human anterior gradient-2 (AGR2) in breast cancer and its clinical and prognostic significance.
  • METHODS: AGR2 expression was assessed in 160 cases of breast cancer and 20 cases of benign breast diseases by immunohistochemistry using tissue chip technology.
  • In addition the expression of ERa, PR and c-erbB-2 in breast cancer was also evaluated.
  • Follow-up information of 5-year duration was available in 127 patients with breast cancer.
  • RESULTS: The expression of AGR2 was significantly higher in breast cancers than that in benign diseases (68.3% vs. 25.0% , P < 0.01).
  • There was a negative correlation between AGR2 expression and the histological grade of breast cancer (P <0.05) , whereas positive correlations was found between the expression of AGR2 and ERalpha (P <0.05), and between the expression of AGR2 and PR (P <0.01).
  • In the subgroup of ERalpha-positive breast cancer, Logistic regression model demonstrated AGR2 and TNM stage were important factors affecting lymph node metastasis (both P < 0.01).
  • Moreover, COX regression model confirmed the expression of AGR2 as an independent prognostic factor among patients with ERa-positive breast cancer (P <0.01).
  • CONCLUSIONS: The abnormal expression of AGR2 may play a role in the pathogenesis and progression of breast cancer.
  • Therefore, AGR2 may be a useful molecular marker for prognostication for patient with hormone-responsive breast cancer.
  • [MeSH-major] BRCA2 Protein / metabolism. Breast Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / genetics. Neoplasm Metastasis / diagnosis. Proteins / metabolism. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Antineoplastic Agents, Hormonal / analysis. Biomarkers, Tumor / analysis. Estrogen Receptor alpha / metabolism. Female. Humans. Immunohistochemistry. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18681322.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / BRCA2 Protein; 0 / Biomarkers, Tumor; 0 / Estrogen Receptor alpha; 0 / Proteins; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.3.4.1 / AGR2 protein, human
  •  go-up   go-down


72. Malhaire C, El Khoury C, Thibault F, Athanasiou A, Petrow P, Ollivier L, Tardivon A: Vacuum-assisted biopsies under MR guidance: results of 72 procedures. Eur Radiol; 2010 Jul;20(7):1554-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinical accuracy of magnetic resonance imaging-guided breast vacuum-assisted biopsy (MR-VAB).
  • RESULTS: Twenty-three patients (median age 51 years) were at high risk (BRCA1 = 11, BRCA2 = 7, familial risk = 5), 23 had a suspected local recurrence of breast cancer.
  • According to histopathology results, 29 lesions were benign, 10 were high-risk (papillary = 2, radial scar = 1, atypical epithelial hyperplasia = 7) and 33 malignant (ductal carcinoma in situ = 8, invasive cancers = 25).
  • CONCLUSION: MRI-guided VAB represents an accurate tool for the histological diagnosis of lesions visible only at MRI.
  • [MeSH-major] Biopsy. Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Bleomycin. Breast / surgery. Dactinomycin. Female. Humans. Middle Aged. Neoplasm Staging. Radiography. Retrospective Studies. Tumor Burden. Vacuum. Vinblastine

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2004 Feb;198(2):240-1 [14759781.001]
  • [Cites] AJR Am J Roentgenol. 2003 Feb;180(2):347-51 [12540431.001]
  • [Cites] Eur Radiol. 2004 Oct;14(10):1725-31 [15248080.001]
  • [Cites] AJR Am J Roentgenol. 2008 Dec;191(6):1798-804 [19020252.001]
  • [Cites] AJR Am J Roentgenol. 2001 Mar;176(3):721-7 [11222213.001]
  • [Cites] AJR Am J Roentgenol. 2007 Aug;189(2):468-74 [17646475.001]
  • [Cites] Acta Radiol. 2006 Nov;47(9):907-13 [17077039.001]
  • [Cites] AJR Am J Roentgenol. 2009 Apr;192(4):1128-34 [19304724.001]
  • [Cites] AJR Am J Roentgenol. 2003 Nov;181(5):1283-93 [14573421.001]
  • [Cites] Radiology. 2006 Jan;238(1):54-61 [16304093.001]
  • [Cites] N Engl J Med. 2004 Jul 29;351(5):427-37 [15282350.001]
  • [Cites] AJR Am J Roentgenol. 2002 Jul;179(1):171-8 [12076929.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jun;184(6):1782-7 [15908530.001]
  • [Cites] AJR Am J Roentgenol. 2009 Feb;192(2):341-51 [19155393.001]
  • [Cites] Eur J Radiol. 2009 Nov;72(2):289-94 [18723305.001]
  • [Cites] Am J Hum Genet. 1991 Feb;48(2):232-42 [1990835.001]
  • [Cites] Lancet. 2005 May 21-27;365(9473):1769-78 [15910949.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3248-58 [18474876.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):386-91 [18202414.001]
  • [Cites] AJR Am J Roentgenol. 2007 Oct;189(4):852-9 [17885056.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):352-3 [18202408.001]
  • [Cites] Radiology. 2007 Aug;244(2):356-78 [17641361.001]
  • [Cites] Radiology. 2007 Sep;244(3):672-91 [17709824.001]
  • [Cites] Eur Radiol. 2002 Jun;12(6):1463-70 [12042955.001]
  • [Cites] Radiology. 1999 Aug;212(2):543-9 [10429716.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):982-90 [16456807.001]
  • [Cites] Eur Radiol. 1999;9(8):1656-65 [10525886.001]
  • [Cites] Radiology. 2007 Aug;244(2):381-8 [17641362.001]
  • [Cites] AJR Am J Roentgenol. 2006 Jun;186(6):1733-6 [16714667.001]
  • [Cites] AJR Am J Roentgenol. 1999 Nov;173(5):1323-9 [10541112.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jul;185(1):183-93 [15972421.001]
  • [Cites] Lancet. 2007 Aug 11;370(9586):485-92 [17693177.001]
  • [Cites] Eur Radiol. 2008 Jan;18(1):168-76 [17609959.001]
  • (PMID = 20119729.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 1CC1JFE158 / Dactinomycin; 5V9KLZ54CY / Vinblastine; VAB protocol
  •  go-up   go-down


73. Sheen-Chen SM, Liu YW, Eng HL, Chou FF: Serum levels of hepatocyte growth factor in patients with breast cancer. Cancer Epidemiol Biomarkers Prev; 2005 Mar;14(3):715-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum levels of hepatocyte growth factor in patients with breast cancer.
  • Elevated hepatocyte growth factor content in tumor tissue was reported to predict a more aggressive biology in non-small cell lung cancer patients.
  • However, there is still limited knowledge about the role of HGF in breast cancer.
  • This study was designed with the aim to elucidate the possible relationship between the preoperative circulating soluble HGF and breast cancer.
  • MATERIALS AND METHODS: One hundred twenty-four consecutive patients with invasive breast cancer undergoing surgery were prospectively included and evaluated.
  • The control group consisted of 35 patients with benign breast tumor (20 with fibrocystic disease and 15 with fibroadenoma).
  • The data on primary tumor staging, age, estrogen receptor status, lymph node status, distant metastases status, histologic grading, and tumor-node-metastasis (TNM) staging were reviewed and recorded.
  • RESULTS: The mean value of serum soluble HGF in patients with invasive breast cancer was 529.05 +/- 123.33 pg/mL and that of control group was 343.00+/- 31.03 pg/mL and the difference was significant (P < 0.001).
  • Furthermore, there were significantly higher serum levels of soluble HGF in patients with negative estrogen receptor (P = 0.035), in patients with poorer differentiated tumor (P < 0.001), in patients with more advanced primary tumor staging (P < 0.001), in patients with more advanced lymph node status (P < 0.001), in patients with distant metastases (P < 0.001), and in patients with more advanced TNM staging (P < 0.001).
  • Thus, preoperative serum soluble HGF levels might reflect the severity of invasive breast cancer and deserve further evaluation.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / pathology. Hepatocyte Growth Factor / blood. Neoplasm Invasiveness
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Humans. Middle Aged. Neoplasm Staging. Prospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767355.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


74. Kowalski W, Mierzwa T, Grabiec M, Laskowski R, Walentowicz M: [Problems in diagnosing breast cancer in women younger than 25 years old]. Ginekol Pol; 2006 May;77(5):376-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Problems in diagnosing breast cancer in women younger than 25 years old].
  • OBJECTIVES: There are several challenges in the diagnosis of breast cancer in young women.
  • Special consideration must be given to the woman's fertility and body image issues, but the difficulty in distinguishing benign from malignant lesions in this group of patients still exists.
  • The aim of our study was to show five cases of breast cancer in young women.
  • MATERIALS AND METHODS: Based on 5 cases of breast cancer in women younger than 25, several methods used in diagnosis in this group of patients were discussed.
  • RESULTS: Diagnosing and treatment of young patients with breast cancer should be performed in specialized oncological centers experienced in dealing with breast cancer in very young women.
  • Because of the possibility of breast cancer in women under 25 years old, each case of breast tumor should be precisely diagnosed, especially by ultrasonography and biopsy (BAC) 2.
  • Each case suspected of breast cancer in young women should be diagnosed in highly equipped and specialized medical center.
  • [MeSH-major] Breast Neoplasms / diagnosis
  • [MeSH-minor] Adult. Age Factors. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Mammography / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16958227.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


75. Esslimani-Sahla M, Thezenas S, Simony-Lafontaine J, Kramar A, Lavaill R, Chalbos D, Rochefort H: Increased expression of fatty acid synthase and progesterone receptor in early steps of human mammary carcinogenesis. Int J Cancer; 2007 Jan 15;120(2):224-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Progestins increase the risk of breast cancer in the hormone therapy of menopause, and progesterone receptor-induced fatty acid synthase (FAS) is a potential therapeutical target of breast cancer.
  • In a first attempt to specify in which lesions at risk of breast cancer progestins might be acting, we have compared the progesterone receptor (PR) and FAS expression in preinvasive breast lesions and in adjacent "normal" mammary glands.
  • We used archive paraffin-embedded tissues from 116 patients, with 164 lesions of increasing histological risk from nonproliferative "benign" breast disease (BBD) to in situ breast carcinomas.
  • The increased FAS expression, in lesions parallel to their increased breast cancer risk, suggests further studies to develop new markers of high-risk lesions and to prevent breast cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / diagnosis. Cell Transformation, Neoplastic / metabolism. Fatty Acid Synthases / analysis. Receptors, Progesterone / analysis
  • [MeSH-minor] Adult. Aged. Early Diagnosis. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17044016.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Receptors, Progesterone; EC 2.3.1.85 / Fatty Acid Synthases
  •  go-up   go-down


76. Dowdy SC, Mariani A, Reinholz MM, Keeney GL, Spelsberg TC, Podratz KC, Janknecht R: Overexpression of the TGF-beta antagonist Smad7 in endometrial cancer. Gynecol Oncol; 2005 Feb;96(2):368-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: We have shown that HER2/Neu may activate the Smad7 promoter in endometrial, ovarian, and breast cancer cell lines.
  • Elevated Smad7 levels could then antagonize the TGF-beta pathway, leading to a reduction in tumor surveillance and potential cancer formation.
  • Our aim was to determine if Smad7 was in fact overexpressed in endometrial cancers and whether Smad7 RNA levels correlated with tumor grade or clinical endpoints.
  • Additionally, the endometrium from 18 patients who underwent hysterectomy for benign indications was collected as a control.
  • Given that many endometrial cancers have been shown to be TGF-beta-unresponsive, Smad7 should be investigated as a potential target to restore TGF-beta responsiveness and limit tumor growth.
  • [MeSH-minor] Cytoskeletal Proteins / biosynthesis. Female. Gene Expression. Humans. Middle Aged. Phosphorylation. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Receptor, ErbB-2 / biosynthesis. Smad2 Protein. Smad3 Protein. Smad7 Protein. beta Catenin

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15661223.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA085257; United States / NCI NIH HHS / CA / CA 085257
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / DNA-Binding Proteins; 0 / RNA, Neoplasm; 0 / SMAD2 protein, human; 0 / SMAD3 protein, human; 0 / SMAD7 protein, human; 0 / Smad2 Protein; 0 / Smad3 Protein; 0 / Smad7 Protein; 0 / Trans-Activators; 0 / Transforming Growth Factor beta; 0 / beta Catenin; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


77. Atallah D, Checrallah A, Rouzier R, Ghossain MA, Chahine G: Retroperitoneal lymphangioleiomyoma mimicking ovarian tumor emerging after tamoxifen therapy. Obstet Gynecol; 2006 Sep;108(3 Pt 2):762-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal lymphangioleiomyoma mimicking ovarian tumor emerging after tamoxifen therapy.
  • CASE: A 44-year-old premenopausal woman with breast cancer treated with adjuvant tamoxifen presented with abdominal distension.
  • We speculate that tamoxifen treatment may play a role in the development of this benign tumor.
  • [MeSH-major] Lymphangiomyoma / diagnosis. Ovarian Neoplasms. Retroperitoneal Neoplasms / diagnosis. Tamoxifen / adverse effects
  • [MeSH-minor] Adult. Breast Neoplasms / drug therapy. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17018494.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


78. Mainiero MB, Cinelli CM, Koelliker SL, Graves TA, Chung MA: Axillary ultrasound and fine-needle aspiration in the preoperative evaluation of the breast cancer patient: an algorithm based on tumor size and lymph node appearance. AJR Am J Roentgenol; 2010 Nov;195(5):1261-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Axillary ultrasound and fine-needle aspiration in the preoperative evaluation of the breast cancer patient: an algorithm based on tumor size and lymph node appearance.
  • OBJECTIVE: The objective of our study was to evaluate the utility of ultrasound-guided fine-needle aspiration (FNA) of the axillary lymph nodes in breast cancer patients depending on the size of the primary tumor and the appearance of the lymph nodes.
  • SUBJECTS AND METHODS: Data were collected about tumor size, lymph node appearance, and the results of ultrasound-guided FNA and axillary surgery of 224 patients with breast cancer undergoing 226 ultrasound-guided FNA.
  • Lymph nodes were classified as benign if the cortex was even and measured < 3 mm, indeterminate if the cortex was even but measured ≥ 3 mm or measured < 3 mm but was focally thickened, and suspicious if the cortex was focally thickened and measured ≥ 3 mm or the fatty hilum was absent.
  • The results of ultrasound-guided FNAs were analyzed by the sonographic appearance of the axillary lymph nodes and by the size of the primary tumor.
  • [MeSH-major] Axilla / pathology. Biopsy, Fine-Needle / methods. Breast Neoplasms / pathology. Lymphatic Metastasis / pathology. Ultrasonography, Interventional
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms, Male / pathology. Breast Neoplasms, Male / surgery. Breast Neoplasms, Male / ultrasonography. Female. Humans. Male. Middle Aged. Neoplasm Staging. Preoperative Care. Prospective Studies. Sensitivity and Specificity. Sentinel Lymph Node Biopsy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] AJR Am J Roentgenol. 2011 Jul;197(1):W194; author reply W195 [21700988.001]
  • (PMID = 20966338.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Ferreira E, Bertagnolli AC, Cavalcanti MF, Schmitt FC, Cassali GD: The relationship between tumour size and expression of prognostic markers in benign and malignant canine mammary tumours. Vet Comp Oncol; 2009 Dec;7(4):230-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship between tumour size and expression of prognostic markers in benign and malignant canine mammary tumours.
  • The aim of this study was to assess the value of tumour size as an indicator of the differentiation of mammary neoplasias in female dogs.
  • The tumour, nodes metastates (TNM) system, based on primary lesion size, the extent of its dissemination to regional lymph nodes and the presence or absence of distant metastases, was applied to 120 female dogs diagnosed with mammary neoplasias.
  • Paraffin blocks from 38 cases were selected and studied by immunohistochemical staining for prognostic and predictive markers of breast cancer.
  • The Kaplan-Meier survival curve was estimated for 110 female dogs.
  • Global survival time was shorter in female dogs with large tumour masses.
  • This study highlights the importance of tumour size as a prognostic indicator of mammary neoplasias in female dogs.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Dog Diseases / metabolism. Gene Expression Regulation, Neoplastic / physiology. Mammary Neoplasms, Animal / pathology. Neoplasms / veterinary
  • [MeSH-minor] Animals. Dogs. Female

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19891693.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


80. Poczobutt JM, Tentler J, Lu X, Schedin PJ, Gutierrez-Hartmann A: Benign mammary epithelial cells enhance the transformed phenotype of human breast cancer cells. BMC Cancer; 2010;10:373
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign mammary epithelial cells enhance the transformed phenotype of human breast cancer cells.
  • However, the role of adjacent benign epithelial cells, which provide initial cell-cell contacts with cancer cells, in tumor progression has not been thoroughly examined.
  • In this report we addressed the question whether benign MECs alter the transformed phenotype of human breast cancer cells.
  • METHODS: We used both in vitro and in vivo co-cultivation approaches, whereby we mixed GFP-tagged MCF-10A cells (G2B-10A), as a model of benign mammary epithelial cells (MECs), and RFP-tagged MDA-MB-231-TIAS cells (R2-T1AS), as a model of breast cancer cells.
  • Moreover, two other models of benign MECs, MCF-12A and HuMECs, also enhanced R2-T1AS colony growth in soft agar and clonogenicity assays.
  • These data reveal that factors secreted by benign MECs are responsible for the observed enhancement of the R2-T1AS transformed phenotype.
  • Co-injecting R2-T1AS cells with G2B-10A cells +/- PFA-fixation, revealed that G2B-10A cells promoted a ~3-fold increase in tumor growth, irrespective of PFA pre-treatment.
  • CONCLUSIONS: Taken together, these data shift our understanding of adjacent benign epithelial cells in the cancer process, from passive, noncontributory cells to an active and tumor-promoting vicinal cell population that may have significant effects early, when benign cells outnumber malignant cells.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Epithelial Cells / pathology
  • [MeSH-minor] Animals. Blotting, Western. Cell Communication. Cell Proliferation. Cells, Cultured. Colony-Forming Units Assay. Culture Media, Conditioned / pharmacology. Cytokines / metabolism. Enzyme-Linked Immunosorbent Assay. Female. Humans. Mice. Mice, Nude. Phenotype. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1995 Feb;95(2):859-73 [7532191.001]
  • [Cites] Science. 2002 Feb 1;295(5556):868-72 [11786607.001]
  • [Cites] J Cell Biol. 1997 Apr 7;137(1):231-45 [9105051.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2A):1063-8 [9615766.001]
  • [Cites] Breast Cancer Res Treat. 2002 Feb;71(3):269-80 [12002345.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Methods. 2003 Jul;30(3):256-68 [12798140.001]
  • [Cites] Breast Cancer Res Treat. 2003 Jun;79(3):287-99 [12846413.001]
  • [Cites] Science. 2004 Feb 6;303(5659):848-51 [14764882.001]
  • [Cites] Oncogene. 2004 Mar 4;23(9):1766-79 [14767472.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 Sep;72(9):3585-9 [1059147.001]
  • [Cites] Nature. 1984 Jun 7-13;309(5968):552-6 [6203040.001]
  • [Cites] J Histochem Cytochem. 1985 Aug;33(8):845-53 [3894502.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5002-11 [10519415.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):839-49 [15516957.001]
  • [Cites] Cell Death Differ. 2005 Feb;12(2):107-14 [15647754.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Breast Cancer Res. 2005;7(3):R274-83 [15987422.001]
  • [Cites] Eur J Cancer. 2005 Nov;41(16):2502-12 [16199153.001]
  • [Cites] Am J Pathol. 2006 Feb;168(2):608-20 [16436674.001]
  • [Cites] Cell Biol Int. 2006 Mar;30(3):227-38 [16427788.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):281-91 [16557280.001]
  • [Cites] Cancer Detect Prev. 2006;30(3):239-47 [16872754.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3871-6 [17360445.001]
  • [Cites] Breast Cancer Res Treat. 2007 Apr;102(2):129-35 [16927176.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1175-83 [17476347.001]
  • [Cites] Nature. 2007 Oct 4;449(7162):557-63 [17914389.001]
  • [Cites] J Clin Invest. 2007 Dec;117(12):3988-4002 [18060036.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4329-34 [18334633.001]
  • [Cites] Biol Reprod. 2008 Apr;78(4):586-94 [18057312.001]
  • [Cites] J Pathol. 2008 Apr;214(5):545-54 [18189329.001]
  • [Cites] Cancer Cell. 2008 May;13(5):394-406 [18455123.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14891-6 [18809919.001]
  • [Cites] Histochem Cell Biol. 2008 Dec;130(6):1079-90 [18953558.001]
  • [Cites] Cell Cycle. 2009 Apr 15;8(8):1127-32 [19282662.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2009 Jun;14(2):145-57 [19350209.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2009 Jun;14(2):87-98 [19381788.001]
  • [Cites] Cell Prolif. 1999 Dec;32(6):351-61 [10646687.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1254-60 [10728684.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12072-7 [11593017.001]
  • [Cites] Int J Cancer. 1997 Mar 28;71(1):42-8 [9096664.001]
  • (PMID = 20637104.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / Cytokines
  • [Other-IDs] NLM/ PMC2913961
  •  go-up   go-down


81. Gorringe KL, Choong DY, Visvader JE, Lindeman GJ, Campbell IG: BARD1 variants are not associated with breast cancer risk in Australian familial breast cancer. Breast Cancer Res Treat; 2008 Oct;111(3):505-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BARD1 variants are not associated with breast cancer risk in Australian familial breast cancer.
  • Several studies in various populations have suggested that non-synonymous BARD1 variants are associated with increased breast cancer risk.
  • Using DHPLC analysis we screened the coding region of BARD1 for variants in 210 probands of breast cancer families including 129 families with no mutations in BRCA1 or BRCA2.
  • These families were ascertained in Australia through the Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).
  • The frequency of five of these variants were evaluated in 258 non-cancer controls and 401 women with sporadic breast cancer.
  • Two variants (Thr598Ile and Ile692Thr) were not detected in any of the 659 sporadic breast cancer cases and controls and were assessed for segregation with breast cancer in the families of the probands.
  • However, neither variant was identified in any other breast cancer case in either family suggesting that these variants are non-pathogenic polymorphisms.
  • We have found no evidence to support involvement of BARD1 in familial breast cancer risk in the Australian population.
  • In addition, three variants previously reported to be pathogenic in other populations are likely to represent benign polymorphisms and therefore we conclude that BARD1 is unlikely to represent a high-penetrance breast cancer susceptibility gene.
  • [MeSH-major] Breast Neoplasms / genetics. Polymorphism, Genetic. Tumor Suppressor Proteins / genetics. Ubiquitin-Protein Ligases / genetics
  • [MeSH-minor] Australia. Case-Control Studies. Female. Gene Frequency. Genetic Predisposition to Disease. Humans. Pedigree. Risk Assessment. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17972171.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BARD1 protein, human; 0 / Tumor Suppressor Proteins; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


82. Li S, Meng L, Zhu C, Wu L, Bai X, Wei J, Lu Y, Zhou J, Ma D: The universal overexpression of a cancer testis antigen hiwi is associated with cancer angiogenesis. Oncol Rep; 2010 Apr;23(4):1063-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The difference of mRNA expression in blood vessels derived from DLBCL and RLNH tissues was detected, and hiwi was overexpressed in tumor vessels of lymphoma.
  • Compared with that of chronic cervicitis (CC), hyperplasia of mammary glands (HMG), ovarian benign lesions (OBL) and endometrium benign lesions (EBL), the expression of hiwi, Ang-2 and Tie-2 was increased significantly in uterine cervical cancer (UCC), breast carcinoma (BC), ovarian cancer (OC) and endometrial cancer (EC) (P<0.01).
  • [MeSH-minor] Angiopoietin-2 / biosynthesis. Angiopoietin-2 / genetics. Argonaute Proteins. Biomarkers, Tumor / analysis. Cell Line, Tumor. Female. Gene Expression. Gene Expression Profiling. Humans. Immunohistochemistry. Oligonucleotide Array Sequence Analysis. Receptor, TIE-2 / biosynthesis. Receptor, TIE-2 / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20204292.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Angiopoietin-2; 0 / Argonaute Proteins; 0 / Biomarkers, Tumor; 0 / PIWIL1 protein, human; 0 / Proteins; EC 2.7.10.1 / Receptor, TIE-2
  •  go-up   go-down


83. Kuo SJ, Hsiao YH, Huang YL, Chen DR: Classification of benign and malignant breast tumors using neural networks and three-dimensional power Doppler ultrasound. Ultrasound Obstet Gynecol; 2008 Jul;32(1):97-102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classification of benign and malignant breast tumors using neural networks and three-dimensional power Doppler ultrasound.
  • OBJECTIVES: To evaluate the use of three-dimensional (3D) power Doppler ultrasound in the differential diagnosis of solid breast tumors using a neural network model as a classifier.
  • METHODS: Data from 102 benign and 93 malignant breast tumor images that had pathological confirmation were collected consecutively from January 2003 to February 2004.
  • We used 3D power Doppler ultrasound to calculate three indices (vascularization index (VI), flow index (FI) and vascularization flow index (VFI)) for the tumor itself and for the tumor plus a 3-mm shell surrounding it.
  • These data were applied to a multilayer perception (MLP) neural network model and we evaluated the model as a classifier to assess the capability of 3D power Doppler sonography to differentiate between benign and malignant solid breast tumors.
  • CONCLUSIONS: 3D power Doppler ultrasound may serve as a useful tool in distinguishing between benign and malignant breast tumors, and its capability may be increased by using a MLP neural network model as a classifier.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Image Interpretation, Computer-Assisted. Imaging, Three-Dimensional. Ultrasonography, Doppler, Color / methods. Ultrasonography, Mammary / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Middle Aged. Neural Networks (Computer). Retrospective Studies. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18521971.001).
  • [ISSN] 1469-0705
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


84. Noetzel E, Rose M, Sevinc E, Hilgers RD, Hartmann A, Naami A, Knüchel R, Dahl E: Intermediate filament dynamics and breast cancer: aberrant promoter methylation of the Synemin gene is associated with early tumor relapse. Oncogene; 2010 Aug 26;29(34):4814-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intermediate filament dynamics and breast cancer: aberrant promoter methylation of the Synemin gene is associated with early tumor relapse.
  • Owing to this multiplicity of potential functions relevant to cancer development, we initiated a study to decipher SYNM expression and regulation in benign human breast tissue and breast cancer.
  • Dot blot array analysis showed significant SYNM mRNA downregulation in 86% (n=100, P<0.001) of breast cancers compared with their normal tissue counterparts, a result that was confirmed by real-time PCR analysis (n=36, P<0.0001).
  • Immunohistochemistry analysis showed abundant SYNM protein expression in healthy myoepithelial breast cells, whereas SYNM expression loss was evident in 57% (n=37, P<0.001) of breast cancer specimens.
  • Indeed, methylation-specific PCR analysis showed tumor-specific SYNM promoter methylation in 27% (n=195) of breast cancers.
  • Demethylating treatment of SYNM methylated breast cancer cell lines with 5-aza-2-deoxycytidine clearly reestablished the SYNM expression.
  • Furthermore, SYNM methylation positively correlated with lymph node metastases (P=0.0177) and advanced tumor grade (P=0.0275), suggesting that SYNM methylation is associated with aggressive forms of breast cancer.
  • We provide first hints that SYNM could represent a novel putative breast tumor suppressor gene that is prone to epigenetic silencing.
  • SYNM promoter methylation may become a useful predictive biomarker to stratify breast cancer patients' risk for tumor relapse.
  • [MeSH-major] Breast Neoplasms / genetics. DNA Methylation. Intermediate Filament Proteins / genetics. Intermediate Filaments / genetics
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cell Line, Tumor. Disease-Free Survival. Epigenesis, Genetic. Female. Humans. Promoter Regions, Genetic. Recurrence

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20543860.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / desmuslin
  •  go-up   go-down


85. Li BJ, Wang JY, Wang HY, Huang XP, Zhang LJ, Long H, Yang MT, Rong TH: [Clinical significance of hMAM mRNA detection in bone marrow of breast carcinoma patient]. Zhonghua Zhong Liu Za Zhi; 2006 Oct;28(10):766-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of hMAM mRNA detection in bone marrow of breast carcinoma patient].
  • OBJECTIVE: To investigate the expression of the human mammoglobin (hMAM) mRNA in bone marrow and its clinical significance in the breast cancer patient.
  • METHODS: Expression of hMAM mRNA was detected using nested reverse transcription polymerase chain reaction (RT-PCR) in the bone marrow aspiration sample from 75 breast cancer patients, 15 patients with benign breast lesions and 8 healthy volunteers as control.
  • The hMAM mRNA was found to be positively expressed by RT-PCR in 21 of 75 breast cancer patients with a positive rate of 28.0%.
  • However, hMAM mRNA expression was not detected in the bone marrow aspiration samples from patients with benign breast lesions and healthy volunteers.
  • The hMAM mRNA expression was positively correlated with axillary nodal involvement and progesterone receptor (PR) status (P < 0.05) as well as Ki67 expression in breast cancer tissue (chi2 = 4.936, P = 0.026), but not with age, tumor size, clinical stage, or estrogen receptor (ER) status (P > 0.05).
  • CONCLUSION: RT-PCR is quite sensitive and has a high specificity in detecting the presence of hMAM mRNA in the bone marrow from breast cancer patients.
  • Thereupon, hMAM mRNA may be useful as a molecular biomarker in detecting disseminated tumor cells (DTC) in the bone marrow of breast cancer patients.
  • [MeSH-major] Bone Marrow / metabolism. Breast Neoplasms / genetics. Breast Neoplasms, Male / genetics. Neoplasm Proteins / genetics. Uteroglobin / genetics
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / genetics. Breast / metabolism. Breast / pathology. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / pathology. Female. Fibroadenoma / genetics. Fibroadenoma / pathology. Humans. Ki-67 Antigen / genetics. Lymphatic Metastasis. Male. Mammaglobin A. Middle Aged. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Receptors, Progesterone / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17366790.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Receptors, Progesterone; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


86. Riedl CC, Pfarl G, Memarsadeghi M, Wagner T, Fitzal F, Rudas M, Helbich TH: Lesion miss rates and false-negative rates for 1115 consecutive cases of stereotactically guided needle-localized open breast biopsy with long-term follow-up. Radiology; 2005 Dec;237(3):847-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lesion miss rates and false-negative rates for 1115 consecutive cases of stereotactically guided needle-localized open breast biopsy with long-term follow-up.
  • PURPOSE: To retrospectively determine the lesion miss rate and false-negative rate of needle-localized open breast biopsy (NLOBB) with stereotactic guidance in a large study population.
  • The mammographic outcomes in all patients with benign results at NLOBB were tracked for at least 2 years.
  • Cases without such mammographic follow-up were cross-referenced with a tumor registry after at least 54 months.
  • Mammographic follow-up data were available for 535 (83%) of 643 NLOBBs with benign results.
  • Mammographic follow-up revealed 11 lesions that were missed with NLOBB, of which five were malignant and six benign.
  • Among the 643 cases, in 108 of them without mammographic follow-up (17%), cross-referencing with a tumor registry did not reveal missed cases of breast carcinoma.
  • CONCLUSION: On the basis of the results of long-term follow-up, the authors noted a lesion miss rate of 1.1% and a false-negative rate of 1.0%, which indicate that NLOBB with stereotactic guidance is an accurate method for diagnosing breast lesions.
  • [MeSH-major] Biopsy, Needle / methods. Breast Diseases / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Diagnostic Errors. False Negative Reactions. Female. Humans. Mammography. Middle Aged. Registries. Retrospective Studies. Stereotaxic Techniques

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] RSNA, 2005
  • (PMID = 16237133.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Yabuuchi H, Matsuo Y, Okafuji T, Kamitani T, Soeda H, Setoguchi T, Sakai S, Hatakenaka M, Kubo M, Sadanaga N, Yamamoto H, Honda H: Enhanced mass on contrast-enhanced breast MR imaging: Lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images. J Magn Reson Imaging; 2008 Nov;28(5):1157-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced mass on contrast-enhanced breast MR imaging: Lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images.
  • PURPOSE: To evaluate the diagnostic accuracy of a combination of dynamic contrast-enhanced MR imaging (DCE-MRI) and diffusion-weighted MR imaging (DWI) in characterization of enhanced mass on breast MR imaging and to find the strongest discriminators between carcinoma and benignancy.
  • MATERIALS AND METHODS: We analyzed consecutive breast MR images in 270 patients; however, 13 lesions in 93 patients were excluded based on our criteria.
  • We analyzed tumor size, shape, margin, internal mass enhancement, kinetic curve pattern, and apparent diffusion coefficient (ADC) values.
  • We added the corresponding categories to these prediction probabilities for malignancy and calculated diagnostic accuracy when we consider category 4b, 4c, and 5 lesions as malignant and category 4a, 3, and 2 lesions as benign.
  • CONCLUSION: The combination of DWI and DCE-MRI could produce high diagnostic accuracy in the characterization of enhanced mass on breast MR imaging.
  • [MeSH-major] Algorithms. Breast / pathology. Breast Neoplasms / diagnosis. Gadolinium DTPA. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Contrast Media. Female. Humans. Middle Aged. Reproducibility of Results. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18972357.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


88. Tsigkou A, Marrelli D, Reis FM, Luisi S, Silva-Filho AL, Roviello F, Triginelli SA, Petraglia F: Total inhibin is a potential serum marker for epithelial ovarian cancer. J Clin Endocrinol Metab; 2007 Jul;92(7):2526-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 2) benign ovarian tumors (n = 25);.
  • 3) breast (n = 10), colon (n = 10), and stomach (n = 10) cancers; and 4) controls (n = 95).
  • In the group of women with epithelial ovarian cancer, blood specimens were also collected after surgical removal of the tumor.
  • In four cases of women with stage IIC mucinous tumor, blood specimens were collected during the follow-up time.
  • RESULTS: Women with epithelial ovarian cancers showed serum total inhibin levels significantly higher than those with benign tumor or with nonovarian tumors or controls (P < 0.001).
  • Total inhibin may therefore be combined with CA-125 for noninvasive diagnosis of epithelial ovarian cancer and may also be a useful serum marker to monitor disease-free intervals.
  • [MeSH-major] Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / diagnosis. Biomarkers, Tumor / blood. Immunoenzyme Techniques / methods. Inhibins / blood. Ovarian Neoplasms / blood. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / diagnosis. Aged. Aged, 80 and over. CA-125 Antigen / blood. Cross-Sectional Studies. Epithelium / pathology. Female. Humans. Middle Aged. ROC Curve

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17473066.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 57285-09-3 / Inhibins
  •  go-up   go-down


89. Li HZ, Gao Y, Zhao XL, Liu YX, Sun BC, Yang J, Yao Z: Effects of raf kinase inhibitor protein expression on metastasis and progression of human breast cancer. Mol Cancer Res; 2009 Jun;7(6):832-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of raf kinase inhibitor protein expression on metastasis and progression of human breast cancer.
  • But its function in breast cancer was not yet clarified completely.
  • We detected RKIP expression in clinical samples of primary breast cancer, breast cancer metastases, and in different breast cancer cells.
  • Compared with the normal breast epithelia, benign breast epithelia, or in situ ductal carcinoma, the expression level of RKIP is decreased in invasive carcinoma and significantly reduced or lost in the metastasis lymph node matched to the invasive carcinoma.
  • To explore the potential role of RKIP in breast cancer metastasis, we studied the effect of RKIP on the malignant phenotypes of the breast cancer cells with ectopically overexpression or knockdown of RKIP.
  • Consistent with these results, in the orthotopic murine models, we observed that overexpression of RKIP in breast cancer cells impaired invasiveness and metastasis, whereas down-regulation of RKIP expression promoted invasiveness and metastasis.
  • These results indicate that RKIP is a metastasis suppressor gene of human breast cancer.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Phosphatidylethanolamine Binding Protein / biosynthesis
  • [MeSH-minor] Analysis of Variance. Animals. Cell Adhesion / physiology. Cell Growth Processes / physiology. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Mice. Mice, Inbred BALB C. Neoplasm Invasiveness. Neoplasm Metastasis. Neovascularization, Pathologic / metabolism. Statistics, Nonparametric. Tissue Distribution


90. Chang RF, Huang SF, Moon WK, Lee YH, Chen DR: Computer algorithm for analysing breast tumor angiogenesis using 3-D power Doppler ultrasound. Ultrasound Med Biol; 2006 Oct;32(10):1499-508
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer algorithm for analysing breast tumor angiogenesis using 3-D power Doppler ultrasound.
  • Angiogenesis provides blood supply for tumor expansion and also increases the opportunity for tumor cells to enter the blood or lymph circulation.
  • Several proangiogenic factors as well as the contribution of the microenvironment to tumor-induced angiogenesis have been identified.
  • Tumor vessels are structurally and functionally abnormal because of an imbalance of these angiogenic regulators.
  • In contrast to normal vessels, tumor vasculature is highly disorganized, tortuous and dilated, with uneven diameter and excessive branching.
  • In investigations into 221 solid breast tumors, including 110 benign and 111 malignant cases, the p values using the Student's t-test for all features were less than 0.05, indicating that the proposed features were deemed statistically significant.
  • The preliminary results show that the proposed method is feasible and has a good agreement with the diagnosis of the pathologists.
  • [MeSH-major] Algorithms. Breast Neoplasms / ultrasonography. Neovascularization, Pathologic / ultrasonography. Ultrasonography, Doppler, Color / methods
  • [MeSH-minor] Adult. Aged. Carcinoma, Ductal, Breast / blood supply. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / ultrasonography. Female. Humans. Image Processing, Computer-Assisted / methods. Imaging, Three-Dimensional / methods. Middle Aged. Neural Networks (Computer). ROC Curve. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17045870.001).
  • [ISSN] 0301-5629
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


91. Guo Z, Wang Z, Li J, Li XD: [Reconstruction with a new type of combined reconstruction following excision of periacetabular tumors]. Zhonghua Wai Ke Za Zhi; 2008 Jun 15;46(12):895-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the reconstructive effect of a new pattern of combined reconstruction after periacetabular tumor resections.
  • METHODS: Between March 2001 and March 2007, tumor resections and new pattern of combined reconstructions which consisted of screw-rod system, acetabular reinforcement shell, antibiotic cement and total hip arthroplasty techniques were performed in 23 patients with periacetabular tumors.
  • Three metastatic bone tumors were also included in this study, and the original sites were thyroid, breast, and ovary.
  • Three primary benign bone tumors belonged to stage III.
  • CONCLUSIONS: This new combined reconstruction is an effective way to rebuild pelvic ring and maintain hip function with low complication rate after periacetabular tumor resections.
  • [MeSH-minor] Adolescent. Adult. Aged. Arthroplasty, Replacement, Hip. Bone Screws. Female. Follow-Up Studies. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035146.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


92. Zhang JJ, Ouyang T, Wan WH, Xu GW, Deng GR: [Detection and significance of APC gene promoter hypermethylation in serum of breast cancer patients]. Ai Zheng; 2007 Jan;26(1):44-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection and significance of APC gene promoter hypermethylation in serum of breast cancer patients].
  • BACKGROUND & OBJECTIVE: Detection of circulating tumor markers is one of current hot spots in tumor research.
  • Free tumor DNA may exist in the peripheral blood of malignant tumor patients.
  • Identical DNA mutations existing in both peripheral serum and primary tumor are found in many kinds of malignant tumors.
  • This study used adenomatous polyposis coli (APC) gene promoter hypermethylation as a tumor marker to investigate the correlations of free tumor DNA to primary tumor and clinicopathologic features of breast cancer.
  • METHODS: The methylation status of APC gene in tumor tissue, paracancer normal tissue, and paired peripheral serum from 84 patients with breast cancer and 10 patients with benign breast diseases were detected by methylation-specific polymerase chain reaction (MSP).
  • RESULTS: The detection rate of APC gene promoter hypermethylation was 45.2% in tumor tissues and 31.0% in paired peripheral sera.
  • APC gene hypermethylation in peripheral serum was significantly correlated to that in tumor tissue (r=0.977, P=0.002).
  • The aberrant methylation of APC gene in tumor tissue and peripheral serum had no correlation to patients' age, tumor stage, tumor size, histological type, and receptor status (P>0.05).
  • No aberrant methylation of APC gene was found in the serum samples from healthy control and the patients without gene methylation in tumor tissue.
  • CONCLUSION: The aberrant tumor gene methylation in peripheral serum of breast cancer patients is significantly correlated to that in primary tumor.
  • [MeSH-major] Breast Neoplasms / genetics. DNA Methylation. DNA, Neoplasm / blood. Genes, APC. Promoter Regions, Genetic / genetics
  • [MeSH-minor] Adult. Carcinoma, Ductal, Breast / blood. Carcinoma, Ductal, Breast / genetics. Carcinoma, Lobular / blood. Carcinoma, Lobular / genetics. Female. Humans. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222366.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


93. Nalini R, Wilma Delphine Silvia CR, Uthappa S: Utility of blood DNA levels in diagnosis of breast cancer. J Cancer Res Ther; 2008 Apr-Jun;4(2):57-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of blood DNA levels in diagnosis of breast cancer.
  • BACKGROUND: Prognostic factors, including both histopathological and biochemical variables, influence the choice of modality and the course of therapy in breast cancer.
  • AIM: To find out if any correlation exists between blood DNA level and tumor stage, size and grade.
  • MATERIALS AND METHODS: This case-control study was carried out on 52 female patients in the age-group of 18-70 years.
  • The cases comprised 25 patients with histopathologically confirmed malignant breast cancer, while 27 patients with benign breast tumors served as the control group.
  • Pearson's test was performed to find out the correlation between blood DNA levels and the TNM stage, tumor size and grade.
  • RESULTS: It was observed that blood DNA levels showed statistically significant correlation with the TNM stage, tumor size and grade.
  • CONCLUSION: The blood DNA level can be utilized as a noninvasive marker to assess tumor aggressiveness.
  • Thus, it can be useful as a prognostic marker and as a marker of tumor burden.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. DNA, Neoplasm / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Case-Control Studies. Female. Humans. Middle Aged. Neoplasm Staging. Neoplasms / diagnosis. Neoplasms / surgery. Tumor Burden

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18688119.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


94. Li C, Grobmyer SR, Chen L, Zhang Q, Fajardo LL, Jiang H: Multispectral diffuse optical tomography with absorption and scattering spectral constraints. Appl Opt; 2007 Dec 1;46(34):8229-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The initial clinical results indicate that the volume fraction of scattering particles in a malignant tumor is higher than that in a benign tumor.
  • [MeSH-minor] Body Water. Breast / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Computer Simulation. Female. Hemoglobins / analysis. Humans. Linear Models. Middle Aged. Oxyhemoglobins / analysis. Particle Size. Phantoms, Imaging. Water / analysis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Water .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18059661.001).
  • [ISSN] 0003-6935
  • [Journal-full-title] Applied optics
  • [ISO-abbreviation] Appl Opt
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA90533
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Oxyhemoglobins; 059QF0KO0R / Water; 9008-02-0 / deoxyhemoglobin
  •  go-up   go-down


95. Lee JH, Kim SH, Lee ES, Kim YS: CD24 overexpression in cancer development and progression: a meta-analysis. Oncol Rep; 2009 Nov;22(5):1149-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The frequency of CD24 expression by immunohistochemistry was 68% in all the carcinomas of the breast, female genital tract, gastrointestinal tract, biliary tract and pancreas, urinary system, prostate and skin.
  • Overall, CD24 was more frequently overexpressed in their carcinomas than their benign lesions (OR=4.21; 95% CI, 1.826-9.731; P=0.001) and was significantly associated with lymph node metastasis (OR=2.41; CI, 1.013-5.720; P=0.047), advanced clinical stages (OR=1.59; 95% CI, 1.244-2.032; P<0.001) and shortened overall survival (HR=2.13; 95% CI, 1.656-2.730; P<0.001).
  • CD24 expression was highly associated with lymph node metastases in breast cancer (OR=3.55; 95% CI, 1.664-7.554; P=0.001), advanced clinical stages (OR=2.22; 95% CI, 1.442-3.418; P<0.001) and lymphovascular invasions (OR=2.78; 95% CI, 1.522-5.068; P=0.001) in urothelial carcinomas and with higher grades in endometrial adenocarcinomas (OR=3.88; 95% CI, 1.548-9.715; P=0.004).
  • CD24 was more frequently and strongly expressed in breast (OR=35.80; 95% CI, 8.907-143.921; P<0.001) and ovarian carcinomas (OR=35.92; CI, 7.156-180.311; P<0.001), than in their benign counterparts.
  • In particular, CD24 may promote cancer development and progression in the breast, ovary and urinary bladder.
  • [MeSH-major] Antigens, CD24 / metabolism. Biomarkers, Tumor / metabolism. Neoplasms / metabolism. Neoplasms / physiopathology
  • [MeSH-minor] Disease Progression. Female. Humans. Lymphatic Metastasis. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19787233.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD24; 0 / Biomarkers, Tumor
  •  go-up   go-down


96. Dillon MF, Quinn CM, McDermott EW, O'Doherty A, O'Higgins N, Hill AD: Needle core biopsy in the diagnosis of phyllodes neoplasm. Surgery; 2006 Nov;140(5):779-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Needle core biopsy in the diagnosis of phyllodes neoplasm.
  • BACKGROUND: Accurate identification of phyllodes neoplasms without surgical intervention is difficult, reducing the ability to manage "benign" lumps non-operatively and impacting on the open benign biopsy rate.
  • Needle core biopsy is considered to be a highly accurate technique in the diagnosis of breast carcinoma.
  • Its accuracy in the diagnosis of phyllodes neoplasm has not been established.
  • RESULTS: Twenty-three patients had phyllodes neoplasm on excisional biopsy with prior core biopsy findings as follows: phyllodes neoplasm (n=2), "equivocal" for phyllodes neoplasm (n=12), fibroadenoma (n=3), benign (n=6).
  • The false negative rate for phyllodes neoplasm was therefore 39% (n=9/23).
  • Of the total biopsy series, 35 patients had a core biopsy suggesting the possibility of phyllodes neoplasm.
  • Of these, 32% (n=11) were found to be phyllodes neoplasm on excision, 3% (n=1) phyllodes neoplasm with breast carcinoma, 6% (n=2) breast carcinoma, and 3% (n=1) sarcoma.
  • When a preference for phyllodes neoplasm (n=4) was stated on the equivocal core biopsies, excision correlated with the stated preference; this correlation also occurred in 90% (n=9/10) of core biopsies where fibroadenoma was favored.
  • CONCLUSIONS: Needle core biopsy rarely produces a definite preoperative diagnosis of phyllodes neoplasm.
  • A diagnosis of fibroadenoma or equivocal phyllodes neoplasm on core biopsy should not prevent excision if clinical suspicion remains.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / diagnosis. Diagnostic Errors. Phyllodes Tumor / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084721.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Di Carlo A, Terracciano D, Mariano A, Macchia V: Matrix metalloproteinase-2 and matrix metalloproteinase-9 type IV collagenases in serum of patients with pleural effusions. Int J Oncol; 2005 May;26(5):1363-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, several MMPs were implicated in creating an environment that supports the initiation and maintenance of tumor growth.
  • Of these patients, 22 had malignant pleural effusion, consisting of 11 breast carcinomas and 11 lung carcinomas (7 squamous cell carcinomas and 4 adenocarcinomas), and 8 patients had benign effusions.
  • The MMP-9/MMP-2 ratio was enhanced in cancer patients compared with benign diseases and healthy individuals.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / enzymology. Breast Neoplasms / pathology. Carcinoma, Non-Small-Cell Lung / enzymology. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / enzymology. Lung Neoplasms / pathology. Matrix Metalloproteinase 2 / blood. Matrix Metalloproteinase 9 / blood. Pleural Effusion / enzymology. Pleural Effusion / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15809729.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


98. Huo L, Gilcrease MZ: Fibroepithelial lesions of the breast with pleomorphic stromal giant cells: a clinicopathologic study of 4 cases and review of the literature. Ann Diagn Pathol; 2009 Aug;13(4):226-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibroepithelial lesions of the breast with pleomorphic stromal giant cells: a clinicopathologic study of 4 cases and review of the literature.
  • Pleomorphic stromal giant cells are occasionally found as an incidental finding in breast tissue but are only rarely seen in fibroepithelial lesions.
  • In this report, we describe 4 fibroadenoma-like lesions of the breast with pleomorphic stromal giant cells.
  • Two cases had focal stromal hypercellularity, one of which was with architectural features borderline between a fibroadenoma and a phyllodes tumor, but none was considered diagnostic of phyllodes tumor.
  • Follow-up for 3 cases at 16 to 59 months revealed no evidence of tumor recurrence.
  • It appears that the presence of pleomorphic stromal giant cells in an otherwise benign fibroepithelial lesion has no adverse clinical significance.
  • [MeSH-major] Breast Neoplasms / pathology. Neoplasms, Fibroepithelial / pathology. Stromal Cells / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Fibroadenoma / diagnosis. Fibroadenoma / pathology. Humans. Middle Aged. Mitosis. Phyllodes Tumor / diagnosis. Phyllodes Tumor / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19608080.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


99. Ohlinger R, Frese H, Schwesinger G, Schimming A, Köhler G: Papillary intracystic carcinoma of the female breast--role of ultrasonography. Ultraschall Med; 2005 Aug;26(4):325-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary intracystic carcinoma of the female breast--role of ultrasonography.
  • We report on a 76-year-old patient with papillary intracystic breast carcinoma.
  • Among all malignant breast tumors, this lesion has an incidence of 0.5-2%.
  • Palpation is not sufficient to distinguish benign from malignant findings.
  • The same applies to mammography, unless the tumor infiltrates the cyst wall.
  • [MeSH-major] Breast Cyst / ultrasonography. Breast Neoplasms / ultrasonography. Carcinoma, Papillary / ultrasonography
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Female. Humans. Palpation. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16123928.001).
  • [ISSN] 0172-4614
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


100. de León DC, Montiel DP, Nemcova J, Mykyskova I, Turcios E, Villavicencio V, Cetina L, Coronel A, Hes O: Human papillomavirus (HPV) in breast tumors: prevalence in a group of Mexican patients. BMC Cancer; 2009;9:26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus (HPV) in breast tumors: prevalence in a group of Mexican patients.
  • BACKGROUND: Breast cancer is one of the main health problems in developed countries, occupying first place in mortality in women.
  • It is well-known that there are risk factors associated with breast cancer development.
  • Nonetheless, in 50-80% of cases known risk factors have not been identified, this has generated the attempt to identify new factors related with this neoplasia as viral infections.
  • The aim of this work is investigate the prevalence of HPV DNA in patients with breast lesions at the Instituto Nacional de Cancerologia de Mexico.
  • METHODS: Fifty-one cases of breast cancer were selected from the files of the institute and compared by age and tumor size with 43 cases of non malignant breast lesions (fibroadenoma, fibrocystic disease and phyllodes tumor).
  • RESULTS: All patients were mexican, mean age was 53.3, median age of menarche was 13 and median tumor size 9 cms.
  • In the group of benign conditions all were negative to HPV-DNA.
  • CONCLUSION: Presence of HPV in breast cancer in our group of cases is high in comparison to other authors; larger numbers of cases need to be analyzed in order to establish the exact role of this virus in the pathogenesis of breast cancer.
  • [MeSH-major] Breast Neoplasms / virology. Papillomaviridae / isolation & purification. Papillomavirus Infections / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA, Viral / isolation & purification. Female. Humans. Mexico. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast. 2007 Apr;16(2):172-7 [17088061.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] J Exp Clin Cancer Res. 1999 Sep;18(3):369-77 [10606184.001]
  • [Cites] Acta Oncol. 1999;38(7):931-8 [10606422.001]
  • [Cites] Anticancer Res. 1999 Nov-Dec;19(6B):5057-61 [10697510.001]
  • [Cites] Breast Cancer. 2000 Jan;7(1):33-6 [11029768.001]
  • [Cites] J Hum Virol. 2001 Nov-Dec;4(6):329-34 [12082399.001]
  • [Cites] J Natl Cancer Inst. 2002 Dec 18;94(24):1832-6 [12488476.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(2):131-7 [14999143.001]
  • [Cites] Pathol Res Pract. 1992 Apr;188(3):384-6 [1320761.001]
  • [Cites] Breast Cancer Res Treat. 1992;21(2):95-100 [1320958.001]
  • [Cites] J Gen Virol. 1995 Apr;76 ( Pt 4):1057-62 [9049358.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jan;53(2):121-35 [10326789.001]
  • [Cites] J Clin Microbiol. 1999 Aug;37(8):2508-17 [10405393.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):946-8 [16222323.001]
  • [Cites] Clin Breast Cancer. 2005 Dec;6(5):391-401 [16381622.001]
  • [Cites] J Pathol. 2006 Aug;209(4):436-44 [16710841.001]
  • [Cites] Breast Cancer Res Treat. 2008 May;109(1):55-8 [17624590.001]
  • (PMID = 19161629.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC2636825
  •  go-up   go-down






Advertisement